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ABSTRACT 
 
TYPE 2 DIABETES MELLITUS (T2DM)  
ONSET AND “REMISSION” 
 
Srikanth Tangelloju 
July 20, 2016 
Background 
Type 2 diabetes mellitus (T2DM) is a progressive disease 
condition. As the disease progresses the function of beta (β) cells (cells 
which regulate insulin) decline, thereby increasing the circulating blood 
glucose levels. If left unmanaged the disease progresses from onset to 
development of T2DM related complications and eventually death. When 
managed, in certain individuals, T2DM onset can be prevented and/or 
slowed down and in certain T2DM individuals, remission is observed. 
There are some known modifiable risk factors such as diet and physical 
activities that are associated with the speed and direction of progression, 
but much is still unknown. In order to develop effective intervention and 
management programs, it is first important to understand the factors that 
predict speed and direction of T2DM progression. 
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Purpose  
This dissertation evaluated T2DM disease progression with three 
key objectives: a) evaluate factors that predict T2DM onset; b) evaluate 
rate of T2DM “remission” and, c) evaluate factors that predict T2DM 
“remission” in Medicare patients 65 years and older who did not undergo 
bariatric surgery. 
Methods 
A retrospective cohort analysis of a Medicare Advantage health 
plan was conducted using administrative data. An individual was identified 
as T2DM if they had: ≥ 2 medical claims for T2DM coded 250.xx excluding 
type 1 diabetes; or ≥ 2 pharmacy claims related to T2DM; or ≥ 2 combined 
medical claims, pharmacy claims for T2DM in 12 months. A T2DM 
individual was in “remission” if they had no T2DM related claims for more 
than 12 months continuously. This is different from the standard American 
Diabetes Association definition of remission which includes HbA1c values 
and hence is represented in quotation (as “remission”). 89,390 individuals 
were evaluated for T2DM onset and 10,059 T2DM individuals were 
evaluated for T2DM “remission” over a period of 8 years from 2008 to 
2015. Cox proportional hazards was used to identify significant variables 
associated with T2DM onset and “remission.” 
  
vii 
 
Results 
The factors that were significantly associated with T2DM onset 
were: male gender; non-white ethnicity (African American, Hispanics); 
statin use; hypertension; hyperlipidemia; heart failure; ulcer of lower limbs; 
atherosclerosis; other retinopathy; angina pectoris; blindness and low 
vision; absence of other chronic ischemic heart disease (IHD) (p<0.05).  
T2DM “remission” does occur without bariatric surgery. 4.97% 
(95% CI, 3.05% - 8.00%) of Medicare Patients 65 years and older met the 
definition of T2DM “remission” in the study cohort. 
The factors associated with T2DM “remission” were no statin use; 
low diabetes complications severity index score (DCSI); no hypertension; 
no hyperlipidemia; no neuropathy; no retinopathy (p<0.05). Race 
(Asian/Hispanic). Other chronic ischemic heart disease (IHD) and female 
gender were significantly associated with T2DM “remission” (p<0.05).   
Conclusions 
In line with previously published studies, the study presented here 
also found that hyperlipidemia, hypertension, gender and race are 
significantly associated with T2DM onset. In addition to these known 
factors, this study identified additional factors associated with T2DM onset 
such as: statin use; hypertension; hyperlipidemia; heart failure; ulcer of 
lower limbs; atherosclerosis; other retinopathy; angina pectoris; blindness 
and low vision and absence of other chronic ischemic heart disease.  
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This study found that in Medicare T2DM patients 65 years and 
older “remission” does occur without bariatric surgery. This study verified 
known factors such as absence of dyslipidemia and race to be associated 
with T2DM “remission.” In addition to these known factors this study found 
that no statin use; low diabetes complications severity index score (DCSI); 
no hypertension; no neuropathy; no retinopathy; presence of other chronic 
ischemic heart disease (IHD) and female gender were significantly 
associated with T2DM “remission.” 
These findings could be used for the development of T2DM related 
disease intervention and management programs. The DCSI score of 
T2DM individuals could be used to help stratify them based on T2DM 
severity for design and individualized, targeted outreach.  
Lastly, in this study hypertension, hyperlipidemia, statins use were 
associated with T2DM onset and T2DM “remission.” Since these factors 
are also associated with metabolic disease, their mutual relation needs to 
be evaluated further, upon availability of laboratory and physician notes 
data. Metabolic disease is a known predictor for T2DM onset and future 
studies might find that metabolic disease might also be a predictor for 
T2DM “remission.” 
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INTRODUCTION 
 
Background to the study 
Type 2 Diabetes Mellitus (T2DM) is a chronic condition wherein the beta cells 
in the body do not produce enough insulin – a hormone that regulates blood 
sugar – or the body does not use insulin well enough (also called insulin 
resistance), or there is complete absence of insulin production. T2DM is 
associated with deleterious macro- and microvascular outcomes (1, 2) and is the 
leading cause of significant morbidities such as kidney failure, lower limb 
amputations, blindness (3). T2DM is the seventh leading cause of death in the 
United States and affects 29.1 million people (4). The total estimated national 
cost of diabetes in the United States in 2012 was more than $245 billion, up from 
$174 billion in 2007 (5).  
T2DM is a progressive disease condition. If left unmanaged the T2DM 
progresses from onset (first occurrence of T2DM) to development of T2DM 
related complications and eventually death. However, when properly managed, 
in certain individuals the T2DM disease progression can be slowed down and in 
certain individuals T2DM “remission” is observed (i.e., no T2DM symptoms after 
onset – detailed definitions below in the literature review section below). 
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Even though there is some available literature on factors associated with 
T2DM onset and “remission” there is a lot of opportunity to further understand 
these factors, especially in the Medicare population who are 65 years or older. 
Understanding the factors that impact T2DM disease progression is important 
because it will help in designing efficient interventions and/or help in creating 
better disease management and wellness programs. In this regards, the following 
study has been done to better understand the T2DM disease progression; 
specifically onset and “remission” of the T2DM, using administrative claims data, 
with three objectives as mentioned below.     
T2DM – Onset 
The first objective of this study is to understand the factors that predict the 
onset of T2DM. Previous studies have identified several risk factors associated 
with onset of T2DM. Some of these risk factors were family history of T2DM, age, 
obesity, and physical inactivity, prior history of gestational diabetes, impaired 
glucose tolerance, dipocytokines, inflammatory factors and hepatocyte factors, 
race/ethnicity, alcohol consumption, smoking/chewing tobacco, diet (6-11), high 
blood pressure (12), appendicectomy (13), and hypothyroidism (14). However, 
there is still additional opportunity to further understand these and other factors 
that are associated with the onset of T2DM, especially in the Medicare 65 years 
and older population. One example of this opportunity is to understand the 
demographic, clinical and pharmacological factors that are associated with onset 
of T2DM.  
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 It is important to understand the factors that are associated with the onset of 
T2DM because T2DM has a long asymptomatic phase (15). People can 
sometimes be unaware that they have diabetes for 4 to 7 years before an actual 
diagnosis (16, 17). Hence understanding these factors will help design better 
T2DM prevention program and help in early intervention. Even in cases where 
T2DM is identified later in its progression (due to late diagnosis), improved 
glycemic control is still beneficial and improves quality of life (18).   
T2DM – “Remission”  
The second objective of this study is to evaluate rate of T2DM “remission” in 
Medicare patients. The third objective of this study is to understand the factors 
that are associated with “remission” of T2DM. Even though it’s rare, T2DM 
“remission” does occur in population without bariatric surgery (19, 20). However, 
there is very little available literature around the factors that are associated with 
“remission” among individuals with T2DM, who received usual care in Medicare 
65 years and older population.  
It is important to understand the factors associated with T2DM “remission” 
because T2DM is a progressive condition (21-23), i.e., if left unmanaged, as 
T2DM progresses the body’s natural ability to regulate blood sugar decreases. In 
many patients the metabolic abnormalities associated with increased blood sugar 
(or hyperglycemia) leads to macrovascular (coronary artery disease, peripheral 
arterial disease, and stroke) and microvascular (diabetic nephropathy, 
neuropathy, and retinopathy) complications (2, 24, 25). Understanding the factors 
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associated with “remission” will help design better T2DM management 
programs.  
In summary, the study presented herein is aimed to enhance our 
understanding about T2DM disease progression, to in turn help identify ways to 
design better interventions. In order to achieve this, the study focuses on the 
following three aims and hypotheses. 
Study Aims and Hypotheses 
a) T2DM – Onset 
Aim 1: What are the factors that predict T2DM onset? 
H0: The sociodemographic and clinical profile of Medicare patients 65 years and 
older, who have T2DM onset, are not statistically different from those who do not 
have T2DM onset. 
HA: The sociodemographic and clinical profile of Medicare patients 65 years and 
older, who have T2DM onset, are statistically different from those who do not 
have T2DM onset. 
b) T2DM – Rate of “Remission” 
Aim 2: What is the rate of T2DM “remission?” 
H0: T2DM Medicare patients 65 years and older, who received usual care without 
bariatric surgery, never achieve T2DM “remission.” 
HA: “Remission” is possible in T2DM Medicare patients 65 years and older, who 
received usual care without bariatric surgery. 
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c) T2DM – “Remission”  
Aim 3: What are the factors that predict T2DM “remission?” 
H0: The sociodemographic and clinical profile of Medicare patients 65 years and 
older, who have T2DM “remission”, are not statistically different from those who 
do not have T2DM “remission.” 
HA: The sociodemographic and clinical profile of Medicare patients 65 years and 
older, who have T2DM “remission”, are statistically different from those who do 
not have T2DM “remission.” 
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LITERATURE REVIEW 
 
Factors Affecting the Health of an Individual 
The United States (U.S.) spent nearly $3.0 trillion, or $9,523 per person in 
2014 on health care costs, which was about 17.5 percent of the gross domestic 
product (GDP) (26). The U.S. is projected to spend nearly $5.4 trillion, or 19.6 
percent of GDP by 2024 on health care costs (27). At its current growth rate, 
spending on health care can adversely affect funding to other areas such as 
education, research and development, infrastructure, defense, and other public 
goods and services (28, 29). The U.S. spends more money per member per year 
on health care than any other country. Despite such costs, the U.S. ranks lower 
on key health measures such as life expectancy at birth, amenable mortality, 
etc., than other comparable nations (30, 31), which suggests that spending on 
health care does not always reflect quality of health (32).   
Prior studies have demonstrated that health care accounts for only 10-
20% of variability in health outcomes, while 80-90% of the variability in health 
outcomes results from other determinants such as individual behavior (40%), 
socioeconomic factors (20%) and genetics (30%) (33-35).  
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These factors (or determinants of health) that either directly or indirectly affect 
the health and well-being of an individual can be broadly categorized into the 
following groups: 
 Health care: Includes sub-components such as access to health care, quality 
of health service and cost of health care services;   
 Health behavior: Health behavioral factors are often modifiable and include 
factors such as level of engagement in one’s own health, motivation to walk, 
diet, physical activity, tobacco consumption, alcohol consumption, 
participation in a wellness program, participation in a disease management 
program and managing stress; 
 Other factors: Includes factors that can or cannot be modified by an 
individual: such as social (factors such as relationships with family and 
friends); economic (factors such as income, net worth); political (factors such 
as government policies, community); current health status of an individual 
(factors such as disabilities, current clinical conditions); biological (factors 
such as genetic); and, physical environmental (factors such as urban/rural, 
pollution) determinants (36) (Figure 2.1). 
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Figure 2.1: Factors effecting the health and wellness of an individual 
 
 
Therefore health of an individual is affected by multiple factors, often 
interacting with each other.  
Health Determinants and Chronic Conditions  
Chronic conditions like cancer, stroke, diabetes, heart disease, respiratory 
diseases etc., are among the leading causes for death, morbidity and disability in 
the U.S. (37). Chronic conditions account for 70 percent of deaths among 
Americans (38) and 75 percent of the cost of health care (39). Most of these 
chronic conditions are highly associated with factors such as: diet; physical 
activity; alcohol and tobacco consumption; social; and, environmental (40-44).  
Chronic diseases are costly yet often preventable. In order to alleviate the 
burden of chronic conditions, public health and health care systems must design 
interventions to address these risk factors. These interventions will help in early 
Health & 
Wellness
eing 
Healthcare 
(Access, cost and quality) 
Other factors 
(Social, 
economic, 
political, 
environmental) 
Health Behavior 
9 
 
detection, slow or stop progression of the chronic condition and reduce 
complications. This will in turn help in improving the quality of life and reduce the 
cost burden on health care and public health systems (45).  
The first step in designing an effective disease intervention is to 
understand the factors that impact the onset of a chronic condition. This 
understanding will not only help designing effective comprehensive disease 
management and wellness programs but also help providers with a better 
understanding about its prognosis and treatment which, will in turn aid in disease 
counseling, and management. 
Diabetes 
Type 1 and Type 2 Diabetes 
Diabetes is a chronic metabolic condition in which the body has a 
decreased ability to secrete insulin, a defect in insulin action or both (46). The 
two main etiopathogenetic categories of diabetes are type 1 and type 2 diabetes. 
Type 1 diabetes is an auto-immune disease that is characterized by an absolute 
lack of insulin secretion. Type 1 diabetes occurs in 5 to 10 percent of diabetes 
cases (47). 
The second and more prevalent category of diabetes is type 2 diabetes 
mellitus (T2DM). T2DM is sometimes also referred as “non-insulin-dependent 
diabetes” or “adult-onset diabetes.” T2DM accounts for 90 to 95 percent of 
diabetes cases (48) and is primarily characterized by worsening of insulin 
resistance and decline in beta cell (or β-cell) function. Beta cells produce and 
secrete insulin – the hormone that regulates blood glucose levels. This glucose 
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imbalance can have a detrimental effect on how the body functions and can lead 
to other comorbidities (more details in the sub section below). This literature 
study focused on diagnosed T2DM. It excluded type 1 diabetes. 
Cost and Importance 
T2DM is the seventh leading underlying cause of death (49). Diagnosed 
T2DM accounts for nearly 10 percent of the cost of health care dollar (50). In 
2012, the total economic cost of T2DM was $245 billion dollars in the U.S. The 
major component of this cost was hospitalization (43% of the total medical cost). 
The medical expenses of people with diagnosed T2DM are 2.3 times that of a 
non-diabetics (5). Worldwide, an estimated 336 million have T2DM and it is 
projected that by 2030 nearly 552 million people will have T2DM (51). 
T2DM is a Progressive Disease Condition 
T2DM Onset 
T2DM can have a long asymptomatic phase (15). People often are 
unaware that they have T2DM for 4 to 7 years before an actual diagnosis (16, 17, 
52). The onset of T2DM is generally preceded by a condition known as pre-
diabetes (53). Pre-diabetes is a condition when the blood sugar is higher than 
normal, but not high enough to be classified as T2DM (54). Without intervention, 
pre-diabetes will most likely lead to the development of T2DM (55).  
In this document the term “T2DM onset” refers to the onset of T2DM and 
not the onset of pre-diabetes. The term “T2DM onset” is used when an individual 
is diagnosed with T2DM for the first time during study period.  
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Risk factors – Onset 
Previous studies have identified several risk factors associated with the 
onset of T2DM such as physical inactivity, alcohol and tobacco consumption, 
diet, family history of diabetes, aging, obesity, prior history of gestational 
diabetes, impaired glucose tolerance, race/ethnicity, (6-11, 56-58), high blood 
pressure (12), appendicectomy (13), hypothyroidism (14), depression and 
anxiety (59). Pharmacological factors such as the use of statins also increases 
the risk of T2DM by 10-12% (60), statins have a dose dependent class effect on 
new-onset T2DM, i.e., the risk of developing T2DM increases with the increase in 
statin dose (61).  Previous studies have hypothesized that statins alter the 
glucose homeostasis thereby causing T2DM onset (62). The speed of T2DM 
progression depends on the age of the first diagnosis, the earlier the onset of 
diabetes the more aggressive the progression or development of comorbidities 
(56, 63).  
Several of these risk factors were previously identified using clinical trials 
and/or case control studies and might not be generalizable to community 
settings. Also, some of these risk factors are not specific to late onset of T2DM, 
especially in the 65 years and older population. Therefore, there is additional 
opportunity to understand factors associated with T2DM progression. There is 
not much literature available on the role of clinical conditions (such as 
retinopathy, neuropathy, peripheral vascular disease and cardiovascular disease) 
and demographics on T2DM onset and remission in T2DM Medicare patients 65 
years or older (Figure 2.2). 
 
 
1
2
 
 
 
 
Figure 2.2: Illustration of the natural progression of T2DM 
 
T2DM is a progressive disease. Glucose is a continuous variable, the use of thresholds such as pre-diabetic, 
T2DM is somewhat arbitrary (64). The speed and direction of progression depends on several factors as 
mentioned in the next sections. 
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T2DM Onset and Progression – The Development of Complications 
T2DM is a progressive condition. As T2DM progresses, the beta cells 
gradually lose their ability to produce insulin, which then progresses to beta cell 
failure and thereby requires insulin replacement (65). Long standing glucose 
imbalances is a key risk factor for macrovascular complications such as 
peripheral arterial disease (66), cerebrovascular (67), cardiovascular disease 
(68-70) and microvascular complications such as neuropathy, retinopathy and 
nephropathy (24, 64, 71-73). T2DM is also associated with other clinical 
conditions such as dyslipidemia (74), hypertension (75), accelerated cognitive 
aging (76), breast cancer, colon cancer, pancreatic cancer, other types of cancer 
(77), mental health such as depression, anxiety, eating disorder (78), Parkinson’s 
disease (79), disabilities (80) and mortality (81). These 
complications/comorbidities (or simultaneous presence of other disease 
conditions) are strongly associated with T2DM progression (64). Depending on 
the number and stage of the complications, these pathologies can cause 
significant disruption to the function of organs and body systems and thus effect 
quality of life (82). These complications and the perceived ability to control the 
disease, impacts the overall quality of life (83, 84). Hence the amelioration and 
prevention of these complications is important and has been a goal of major 
research in the recent years (85).  
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Complications associated with T2DM 
Hyperglycemia causes damage to vascular system. T2DM causes both 
macrovascular (hypertension, hyperlipidemia, cardiovascular, cerebral vascular 
disease, and peripheral vascular disease) and microvascular diseases 
(retinopathy, nephropathy, and neuropathy) (86). This section discusses the key 
vascular complications associated with T2DM. 
Diabetic retinopathy: Retina is one of the most vascular regions in the human 
body. The damage due to hyperglycemia can vary depending on the severity of 
damage to the vascular system ranging from blurry vision to compete blindness. 
Nearly 21% of patients diagnosed T2DM have retinopathy at the time of onset 
(87). 
Diabetic nephropathy: Diabetic nephropathy is also one of the important 
vascular complications and a major cause of chronic kidney disease (88).  
Diabetic neuropathy: Neuropathy causes loss of sensation in the feet, which in 
turn causes callous formation. Neuropathy is associated with foot ulcers, non-
healing skin wounds and ulcers (89).  
Cardiovascular diseases: Cardiovascular diseases associated with T2DM are 
the primary cause of mortality and morbidity. This is the primary reason why 
T2DM is the seventh largest cause of death in the United States (3).  
Cerebrovascular: Cerebrovascular disease in T2DM is mainly because of 
atherosclerosis. The brain vessels disease can cause cognitive impairment and 
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is a risk factor for dementia, Alzheimer’s disease, transient ischemic attack (TIA) 
and stroke (90).  
Peripheral Vascular Disease (PVD): The key factors for PVD are vascular 
smooth muscle cell dysfunction, inflammation, hypercoagulability and endothelial 
dysfunction (91). PVD primarily involves aneurysm and claudication. 
Other complications mentioned above such as cancers, cognitive aging, death, 
are beyond the scope of this literature review. 
Metabolic Syndrome and T2DM 
Metabolic syndrome is characterized by a group of risk factors that raises 
the risk of heart disease and other health problems such as stroke or diabetes. 
These risk factors include large waistline, high triglyceride level, low HDL 
cholesterol level, high blood pressure, high fasting blood sugar (92, 93). Patients 
with metabolic syndrome are at a higher risk of developing T2DM by threefold 
and the risk of developing cardiovascular diseases by two fold (94-96). This 
study does not use metabolic syndrome as a predictor or classifier, due to the 
lack of HbA1c data and glucose data. 
Diabetes Complications Severity Index (DCSI Score) 
The severity of the above mentioned T2DM complications varies from one 
patient to another. Therefore the severity of the disease varies depending on the 
stage of diabetes (pre-diabetes vs. T2DM) and/or the presence of T2DM related 
complications. An individual with pre-diabetes and no complications is 
considered having the least severity due to T2DM, while a T2DM patient with 
 
 16   
 
multiple complications would be considered having the most severity due to 
T2DM (more details below). Individuals who die due to T2DM related 
complications theoretically have the most severe complications, but are excluded 
in the study presented below.  
The complications associated with T2DM usually develop simultaneously or 
consecutively rather than independently. Hence a simple count of complications 
will not provide sufficient measure of T2DM disease progression and severity. 
Therefore an indicator (or score) was previously developed to quantify the 
severity of diabetic complications (97, 98). This indicator is called the Diabetes 
Complications Severity Index (DCSI) and models the severity of diabetes 
complication at any given point of time in the patient’s life. DCSI can hence be 
used to access patient’s risk of adverse outcomes (like hospitalization or death). 
Administrative claims (medical, pharmacy and lab data) are used to calculate 
DCSI. This score was subsequently validated (99) and adopted by other 
researchers (100-104). This study uses DCSI scores to quantify T2DM diabetes 
severity.  
T2DM Onset Followed by “Remission” 
T2DM disease progression is generally regarded as irreversible (105). 
However with certain types of interventions such as bariatric surgery, metabolic 
surgery, lifestyle efforts (e.g., weight loss and exercise), in certain individuals 
T2DM “remission” is observed. This literature review excluded remission due to 
bariatric/metabolic surgery because the focus of the study was to understand the 
factors associated with remission in a non-surgery based setting. 
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Remission – Definition 
The American Diabetes Association (ADA) has proposed the following definitions 
for T2DM remission (106). 
a) Partial remission: Partial remission is defined as sub-diabetic hyperglycemia 
without active pharmacologic therapy or ongoing procedures for at least 1 year. 
Sub-diabetic hyperglycemia is when HbA1c < 6.5% and/or fasting glucose 100–
125 mg/dL [5.6–6.9 mmol/l]. 
b) Complete remission: Complete remission is defined as “normal” measures of 
glucose metabolism without active pharmacologic therapy or ongoing procedures 
for at least 1 year. Normal measure of glucose metabolism is when HbA1c in the 
normal range, < 5.7%, < 39 mmol/mol, fasting glucose < 100 mg/dl [5.6 mmol/l])   
c) Prolonged remission: Complete remission for at least 5 years.  
Since, T2DM is a chronic disease and individuals who go into remission are at a 
high risk of relapse, the term cure is not used by ADA for even prolonged 
remission because cure is generally the restoration of health, whereas remission 
is the abatement of signs and symptoms of disease (106). 
Risk factors – Remission 
Current understanding about T2DM remission due to non-bariatric 
intervention is limited. The recent post hoc randomized controlled study from the 
Look AHEAD (Action for Health for Diabetes) and the 2014 Kaiser Permanente 
study suggest that factors such as age, race, time since diagnosis, baseline 
HbA1c level and taking diabetes medication at baseline are associated with 
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T2DM remission (19, 20, 107). There is also limited information on how T2DM 
remission occurs in a usual care setting especially in the Medicare patients 65 
years or older.  
T2DM Management 
The American Diabetes Association’s (ADA’s) “Standards of Medical Care 
in Diabetes – 2016” provided details on several components of T2DM 
management, care, general treatment goals, and tools to evaluate the quality of 
care (108). Reviewing these factors for the study is important because an 
individual who is managing their T2DM will favorably alter the disease 
progression (109). Therefore this section of the literature review highlights some 
of the key T2DM management and interventions.  
Treatment of T2DM generally includes lifestyle interventions and/or 
medical interventions (or non-lifestyle related diabetes management).  
T2DM - Lifestyle Interventions 
Lifestyle interventions of diabetes generally include education, nutritional 
therapy, blood sugar monitoring and physical activity.  
Education: The first and probably the most important component of diabetes 
management is patient education, i.e., make the patient aware of the disease 
condition (110). Such educational programs may include information about the 
complexity of diabetes, its potential impact if left unmanaged, information on 
healthy eating, methods to stay physically active, etc. Education is effective in 
improving outcomes related to diabetes (111-116). However, there is no “one 
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size fits all” educational program for diabetics. At a macro level, the role of 
education is well established, for example, it is demonstrated that education 
programs that help in modifying behavioral and psychosocial aspects have 
improved health outcomes (117-119). However, when designing, testing and 
implementing an education program at a micro level to a particular diabetic 
individual or group, several other variables such as trust on the source of 
education material, leadership, partnership, might also be important (120). 
Nutrition: Nutrition is a key component of diabetes management. However, as 
with education, there is no single nutritional strategy that works the best for all 
diabetics (121). A nutritional management program is designed to motivate 
individuals with T2DM to make healthy food choices. 
Physical activities:  Regular physical activities reduce the risk of diabetic 
progression (122). American Diabetes Association recommends 90 minutes of 
vigorous physical activity or 150 minutes of moderate physical activity per week. 
As cardiorespiratory fitness and physical activity increases, the associated health 
benefits also increase proportionally (123-125).  
Previous participation in physical activities were difficult to quantify unless 
under study conditions. However with the advent of technology, numerous 
devices such as pedometers, smart watches etc. are now available that can 
accurately and passively capture some of the physical activity data and 
information.  
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T2DM – Medical Intervention – Pharmacy 
Medical intervention can be in the form of pharmaceuticals such as oral 
anti-diabetic medications and/or injectable therapies such as insulin. Providers 
use several different types of T2DM medication. These medications might be 
used individually or in combination, depending on requirement and may include 
monotherapy e.g., use of metformin, dual therapy e.g., metformin + 1st line agent 
like Alpha-glucosidase inhibitors, triple therapy e.g., metformin + 1st line agent 
+2nd line agent like Colesevelam, or insulin, etc.  (126, 127).  
T2DM – Medical Intervention – Surgery 
In certain obese individuals with T2DM, medical intervention may also 
include medically assisted weight loss, using surgery. Weight loss is generally 
considered first in T2DM disease management (128), especially in obese T2DM 
patients. Obese T2DM patients with sustained weight loss have been shown to 
improve glycemic control. In certain patients weight loss can be achieved by 
intervention strategies such as diet, physical activity, behavioral therapy, lifestyle 
intervention, pharmacological therapy, bariatric (“weight-loss”) surgery and other 
metabolic surgeries such as gastric banding (or procedures that involve 
resecting, bypassing or transposing sections of the stomach and small intestine). 
Bariatric surgery commonly includes gastric bypass such as Roux-en-Y-gastric 
bypass (RYGBP), sleeve gastrectomy such as Laparoscopic Sleeve 
Gastrectomy, adjustable gastric band, and biliopancreatic diversion with 
duodenal switch (BPD/DS) (129). Bariatric and metabolic surgeries are often 
 
 21   
 
considered as an effective weight loss treatments for certain individuals with 
severe obesity especially amongst adults with BMI ≥ 35 kg/m2.  
Bariatric surgery has been proved to be effective in treating T2DM patients 
whose BMI is 35 kg/m2 or higher (130) with a success of achieving T2DM 
remission between 24% and 95% (131, 132). Bariatric surgery is different from 
lifestyle intervention because not every individual qualify for a bariatric surgery, 
also the mechanism for remission after bariatric surgery is still unclear and might 
be different from the mechanism of remission following lifestyle intervention 
(132). Therefore individuals with bariatric surgery were excluded from the 
analysis.  
T2DM - Disease Management Programs 
Wellness Programs 
Wellness programs utilize education (133), behavior modification (134), 
counseling (135), and incentives (136), etc., to help make better health and 
wellness choices. Wellness programs are generally offered either through 
workplace (called workplace wellness programs) or directly to individuals (e.g., 
self-employed, Medicare members, etc.) (137) (Figure 2.3).  
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Figure 2.3: Channels through which wellness programs are offered 
 
The current study focused only on “A) Individual/non-employees – Health 
Insurance + Wellness program.” 
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Lifestyle interventions are a major component of wellness programs that 
are offered by health insurance companies to their members (or policy holders). 
These wellness programs are generally offered as an add-on to the health 
insurance coverage for members. A wellness program could have multiple 
“lifestyle intervention” related components such as education, diet, promoting 
physical activity, campaigns related to medication adherence, annual health 
assessments, etc. (138). Each “lifestyle intervention” component could have sub-
components. For example, the component “promoting physical activity” might 
include sub-components like promoting walking, gym and yoga, 5k events for 
encouraging running. Some members might prefer walking and some might 
prefer going to a gym, while some might prefer a combination of these activities. 
Wellness programs are generally offered in multiple formats to provide a “variety 
of choices” to the participants and to foster those with preferential participation. 
This study presented herein does not differentiate the type of lifestyle intervention 
and only considered any non-bariatric lifestyle intervention. 
Disease Management Programs 
Health insurance providers also have several disease management programs 
which are separate from the wellness programs. These disease management 
programs are designed specifically for each disease and often provided in 
addition to wellness programs. For example, the diabetes disease management 
program might provide clinical guidance to their members who are pre-diabetic or 
diagnosed with T2DM.  
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Gap in Literature  
A well designed lifestyle intervention; either as a standalone program or as 
part of a comprehensive wellness program or T2DM disease management 
program, includes components such as diet, exercise, education/counseling, 
smoking cessation, behavior modification (139). Some of these lifestyle 
interventions are hypothesized to achieve key outcomes such as decreased 
health care cost, improved quality of life, improved health outcomes, stop or 
delay the onset of T2DM, and stop or delay progression of T2DM complications 
(110, 140). It is also noted that a single intervention will not be able to address all 
the above factors at the same time, and might need multiple lifestyle 
interventions at various phases of T2DM disease progression.  
Some well-designed lifestyle intervention programs aimed at individuals 
with T2DM have shown positive health outcomes (125, 141-143). Some lifestyle 
intervention programs work, while some do not (144). Within those that work, 
their level of success varies greatly from one program to another. Success of 
these lifestyle intervention programs depend largely on whose perspective the 
program is being implemented and may include: stakeholder (provider, insurance 
agency, self); the goals of the program (to make money vs. keep individuals 
healthy); program design (components/services offered in the lifestyle 
intervention program); implementation (level of activation of the program, 
incentives, penalties); and most importantly how the program is evaluated 
(quality of life, unhealthy days, absenteeism). An effective lifestyle intervention 
program is highly customized and engages the intended audience at an 
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“individual level.” In order to achieve high level of customization, it is imperative 
to understand questions such as: “what works?”; “how to engage?” and, “what 
needs to be improved?” The study presented here does not evaluate all these 
questions but focusses only on understanding the factors that predict T2DM 
onset and “remission.”  
Lifestyle interventions applied as a community based strategy are not 
effective and need to be tailored (145). The first step in designing a 
comprehensive lifestyle intervention programs for T2DM is to understand T2DM 
progression. T2DM progression has the following components; a) before onset of 
T2DM (prevention), factors associated with onset of T2DM; b) after onset of 
T2DM (treatment/management), factors associated with progression and factors 
associated with “remission.”  
T2DM Onset  
As discussed above, there is still a gap in the literature about the 
association of clinical conditions (such as retinopathy, neuropathy, peripheral 
vascular disease and metabolic disease) and demographics with the onset of 
T2DM in Medicare patients 65 years and older.  
T2DM “Remission” 
There are unanswered questions about the role of lifestyle interventions in 
T2DM “remission.” For example, what are the demographic, clinical factors that 
are associated with individuals who have T2DM “remission” without bariatric 
surgery?  
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Even though lifestyle intervention is considered more effective than medical 
intervention for pre-diabetic patients and patients with impaired glucose tolerance 
(146-148), the role of lifestyle interventions for T2DM “remission” is still unclear. 
Though there is already some evidence for the possibility of T2DM “remission” 
outside bariatric surgery, the rate of incidence is relatively low. Hence there is 
value in understanding the demographic, pharmacological and clinical factors 
that are associated with T2DM “remission” without bariatric surgery.  
In summary, the purpose of the study is to evaluate the following two questions 
1. Progression to Onset: What are the factors that predict T2DM onset? 
2. Progression to “Remission”: What are the factors that predict T2DM 
“remission?” 
Importance of this Study 
a) Monetary Impact: Potential saving of $3 to $4.6 billion in savings annually in 
Kentucky (149). 
b) Quality of life: More healthy and happy days due to reduced morbidity. 
c) The need for efficient intervention:  
Stakeholders such as health care systems, providers and payors do not have 
unlimited resources to use blanket approaches for intervention. Organizations 
are using data analytics to help design efficient lifestyle intervention 
programs. Data mining can provide valuable and actionable insights. These 
insights can be used to design, test analyze, learn and revise specific 
hypothesis. This continuous “test and learn” process will help optimize the 
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allocation of scarce resources to high potential wellness initiatives (Figure 
2.4). This will in turn help target the right individual with the right intervention. 
Figure 2.4: Test and learn cycle of a wellness program implementation 
 
Also, rather than targeting the entire population for specific wellness 
component, predictive analytics (like predictive models, segmentation, clustering) 
of data can be used to create targeted high impact intervention to specific 
audiences, thereby increasing adoption and success of the intervention. 
d) Compression of Comorbidity 
Compression of comorbidity is to postpone the age of the first onset of 
chronic infirmity so that the lifetime illness burden is compressed into a shorted 
period toward the age of death (150). In order to achieve compression of 
morbidity, it is important to understand the prognosis of the disease and the 
factors that impact the progression.  
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METHODS 
 
Study Design 
 
The study is a retrospective cohort analysis using administrative Medicare 
Advantage Prescription Drug (MAPD) health plan data from a large Managed 
Care Organization (MCO). This administrative data included enrollment, medical 
claims and pharmacy claims data. This data were collected during the standard 
course of care. It was not originally collected for the purpose of research or any 
new study of human or animal subjects. Prior to the start of the study this study 
protocol was reviewed and approved by the University of Louisville Institutional 
Review Board. This study was also reviewed by the MCO’s review board.  
De-identification:  
The data was de-identified before analysis using industry standard de-
identification process. The following are some of the example identifiers that 
were removed from the data as part of the MCO’s de-identification process 
a. Names. 
b. All geographic subdivisions smaller than a state, including street address, 
city, county, precinct, zip Code, and their equivalent geographical codes. 
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c. All elements of dates (except year) for dates directly related to an individual, 
including birth date, admission date, discharge date, date of death; and all 
ages over 89 and all elements of dates (including year) indicative of such age. 
d. Telephone numbers, facsimile numbers, electronic mail addresses, social 
security numbers, medical record numbers, health plan beneficiary numbers, 
account numbers, certificate/license numbers, vehicle identifiers and serial 
numbers, including license plate numbers, device identifiers and serial 
numbers, web universal resource locators (url), internet protocol (IP) address 
numbers, biometric identifiers, including fingerprints and voiceprints, full-face 
photographic images and any comparable images.  
e. Any other unique identifying number, characteristic, or code such as social 
media handles/profile names/ids, mac address, mobile device id number or 
mobile unique device ID. 
Study Cohort 
The federal government offers original Medicare insurance, which includes 
Medicare Part A (Hospital Insurance) and Medicare Part B (Medical Insurance). 
Part C (or Medicare advantage) is offered through private insurance companies 
and include the benefits of Part A, Part B and sometimes the optional Part D 
(Prescription Coverage) along with several choices of programs and services. 
Individuals can only be enrolled in Part C if they qualify for Medicare Part A and 
Part B.  
The private MCO offers Medicare Advantage Prescription Drug Plan 
(MAPD) a Part C plan, which has the benefits of Medicare Part A, Part B and 
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Part D, to individuals (Individual MAPD) and groups (Group MAPD). The source 
population for this study are individuals who enrolled (members) in MCO’s 
individual MAPD plan. The steps taken to create the aggregated dataset are 
mentioned below. 
Data Aggregation – Steps, Inclusions and Exclusions 
The data aggregation was done in Hadoop (using Spark, Scala and Hive). 
Hadoop is an open source software framework for distributed processing and 
distributed storage of very large datasets (151). Processing was done in Hadoop 
because of the volume of the data. Means and frequencies were calculated in 
Hadoop. This data was then moved into SAS 9.2 (SAS Institute Inc., Cary NC) to 
calculate rate for T2DM onset and “remission.”   
Step1: Identify active enrollees: Identify active MAPD enrollees who were 
active with the MCO in 2015. There were > 2.4 million individuals who met this 
criteria. 
Step2: Include only Medicare age-ins: The study included only those members 
whose initial eligibility for Medicare enrollment was based on their age. An 
individual can qualify to receive Medicare benefits if they are at least 65 years in 
the year of their Medicare enrollment and meet certain additional enrollment 
criteria. Therefore this study excludes those people who qualify for Medicare for 
any other reasons such as disabilities or end stage renal disease (ESRD). There 
were 1.7 Million individuals who met this criteria. 
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Step 3: Exclusions: Excluded individuals who did not have continuous 
Individual MAPD coverage with MCO from January 2008 to December 2015. 
This ensured that the inclusion of MAPD individual who had both medical and 
pharmacy coverage through the MCO continuously for eight years with the MCO. 
Individuals with bariatric surgery, polycystic ovary syndrome, lipodystrophy, 
nephropathy, type 1 diabetes, lived in Puerto Rico, steroid induced T2DM were 
excluded from the study. These conditions were identified using a combination of 
diagnostic codes, procedure codes, and therapeutic drug description. There were 
121,862 individuals in the study cohort after this exclusion. 
Step4: Identify T2DM: T2DM individuals were identified using administrative 
medical and pharmacy claims using the following criteria; at least two diagnoses 
of T2DM (International Classification of Diseases, Ninth Revision, Clinical 
Modification [ICD-9-CM] and/or (International Classification of Diseases, Tenth 
Revision, Clinical Modification [ICD-10-CM]; at least two pharmacy scripts related 
to T2DM; at least 2 claims (medical or pharmacy) related to T2DM. A minimum of 
two claims was used in the identification of T2DM because this would help 
exclude patients who were miscoded and patients who were suspected to have 
T2DM but were never formally diagnosed. T2DM status was identified for each 
year from 2008 to 2015.   
Using eight years of data, each individual was assigned into a group 
based on their T2DM status over 8 years (Table 3.1). Each individual was 
assigned 8 character sequence to represent their T2DM status for each year 
from 2008 to 2015, where character at position 1 represents T2DM status of 
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2008; position 2 represents T2DM status of 2009 and so on. So a sequence 
00000000 represents an individual who had no diabetes in any year 2008 to 
2015 and a sequence 00000011 represents an individual who was identified to 
have no T2DM from 2008 to 2013 and had a T2DM onset in 2014 and continued 
to have T2DM in 2015. These groups were then categorized into three cohorts: 
a) onset cohort; b) “remission” cohort; and, d) other cohort as described below. 
Table 3.1: Exclusions 
T2DM Sequence§§ n %  
Always T2DM 11111111 9,559 7.8% Onset cohort 
No T2DM 00000000 85,076 69.8% “Remission” cohort 
“Remission” 
11111110, 11111100, 
11111000, 11110000 500 0.4% 
“Remission” cohort 
Onset 
00000001, 00000011, 
00000111, 00001111 4,314 3.5% 
Onset cohort 
Newly diagnosed 
+ “remission” 
00000010, 00000110, 
00000100, 00001100 2,330 1.9% 
Excluded 
Other 
combinations XXXXXXXX 20,083 16.5% 
Excluded 
Total 121,862 100.0% 
 
 
§§0 = no T2DM and 1 = presence of T2DM 
a) T2DM onset cohort 
In order to be included in the onset cohort, individuals were required to 
have no T2DM in the year 2008, 2009, 2010 and 2011. This condition enabled to 
establish a natural history of T2DM for at least four years. The occurrence of 
onset was evaluated in 2012, 2013, 2014 and 2015. Also, once an individual was 
diagnosed with T2DM, only those who continued to have T2DM in the 
subsequent years till the end of the study were considered to have a T2DM onset 
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(Table 3.2). Individuals who did not have T2DM any year from 2008 through 
2015 were considered as part of the no onset group (Table 3.2). 
Table 3.2: T2DM onset 
T2DM Diagnosis   
2008§ 2009 2010 2011 2012 2013 2014 2015 PATTERN§§ Description 
NO NO NO NO NO NO NO NO 00000000 
No Onset  
( n = 85,076) 
NO NO NO NO NO NO NO YES 00000001  
NO NO NO NO NO NO YES YES 00000011 Onset 
NO NO NO NO NO YES YES YES 00000111 (n = 4,314) 
NO NO NO NO YES YES YES YES 00001111   
NO NO NO YES YES YES YES YES 00011111 Onset  
NO NO YES YES YES YES YES YES 00111111 (Excluded) 
NO YES YES YES YES YES YES YES 01111111   
NO NO NO NO NO NO YES NO 00000010 No continuous 
Onset (Excluded) NO NO NO NO NO YES NO YES 00000101 
 
§NO = no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis 
§§0 = no T2DM and 1 = presence of T2DM 
The onset cohort had a total of 89,390 individuals. The censored variable 
was binary (0, 1). The value of 1 was assigned for individuals who had a T2DM 
onset (n= 4,314) and a value of 0 was assigned for individuals who did not have 
T2DM in the eight years of study (n = 85,076). 
b) “Remission” cohort 
The definition of “remission” in this study was different from that used by 
American Diabetes Association (ADA), because of the lack of HbA1c data. An 
individual was considered to be in “remission” if they had two or more T2DM 
related claims in previous years and had no T2DM related claim in the given 
year. Some individual’s experience T2DM relapse followed by a year or two 
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years of “remission.” Such individuals were excluded from the study i.e., upon 
“remission” T2DM individuals were required to continue to have no T2DM related 
claims till the end of study period i.e., 2015. Also, to be included in the T2DM 
“remission” study cohort, individuals were required to have T2DM in the year 
2008, 2009, 2010 and 2011 and either continue to be diabetic (no “remission” 
group) or go into “remission” (“remission” group). This condition enabled to 
establish a natural history of T2DM for at least four years. T2DM relapse can 
happen in some individuals after “remission”. Those individuals who had relapse 
after first “remission” were excluded from the study, in order to focus on only 
those individuals who had continuous “remission” (Table 3.3). 
Table 3.3: T2DM “Remission” 
T2DM DIAGNOSIS   
2008§ 2009 2010 2011 2012 2013 2014 2015 PATTERN§§ Description 
YES YES YES YES YES YES YES YES 11111111 No “Remission” 
 ( n = 9,559) 
YES YES YES YES YES YES YES NO 11111110  
“Remission” 
(n = 500) 
YES YES YES YES YES YES NO NO 11111100 
YES YES YES YES YES NO NO NO 11111000 
YES YES YES YES NO NO NO NO 11110000 
YES YES YES NO NO NO NO NO 11100000 “Remission”  
(Excluded) YES YES NO NO NO NO NO NO 11000000 
YES NO NO NO NO NO NO NO 10000000 
YES YES YES YES NO NO YES YES 11110011 “Remission” + Relapse 
(Excluded) YES YES YES YES NO YES NO YES 11110101 
 
§NO = no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis 
§§0 = no T2DM and 1 = presence of T2DM 
 
The “remission” cohort had a total of 10,059 individuals. The censored 
variable was binary (0, 1). The value of 1 was assigned for individuals who had a 
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T2DM “remission” (n= 500)) and a value of 0 was assigned for individuals who 
had T2DM every year from 2008 to 2015 (n = 9,559). 
c) Other Cohort:  
Among the 121,862 individuals in the study frame there were 18.4% 
(16.5% + 1.9%) individuals who had T2DM combinations that did not meet our 
definition of onset or “remission” as mentioned above. The individuals were 
excluded from the analysis in order to account for only those individuals who 
continued to have the event (either onset or “remission”) after its first occurrence 
and excluded relapses. This study could have included these 18.4% individuals 
in the analysis, but the behavior of individual who had a relapse is likely different 
from those who did not have a relapse, a choice was made to exclude them from 
this study.  
Step5: Independent variables: After accounting for the inclusions and 
exclusions, the remaining members were included in the analytical dataset. 
These members are then tagged with additional data components. Primary topics 
and data components are mentioned below: 
a) Clinical tags: Clinical tags were binary indicators (member had clinical 
condition Y/N) for each year from 2008 to 2015. These clinical conditions are 
the key macrovascular and microvascular disease conditions that are 
commonly associated with T2DM. Administrative medical claims were used 
for identification of these clinical tags as described before (98). These clinical 
conditions include; retinopathy (diabetic ophthalmologic disease, background 
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retinopathy, other retinopathy, retinal edema, cystoid macular 
edema/degeneration (CSME), other retinal disorders, proliferative retinopathy, 
retinal detachment, blindness, vitreous hemorrhage); nephropathy (diabetic 
nephropathy, acute glomerulonephritis, nephrotic syndrome, hypertension, 
nephrosis, chronic glomerulonephritis, nephritis/nephropathy, chronic renal 
failure, renal failure not otherwise specified, renal insufficiency); neuropathy 
(diabetic neuropathy, amyotrophy, cranial nerve palsy, mononeuropathy, 
Charcot’s arthropathy, polyneuropathy, neurogenic bladder, autonomic 
neuropathy, gastroparesis/diarrhea, orthostatic hypotension) cerebrovascular 
(transient ischemic attack, stroke); cardiovascular (atherosclerosis, other 
ischemic heart disease, angina pectoris, other chronic IHD, myocardial 
infarction, ventricular fibrillation arrest, atrial fibrillation arrest, other 
atherosclerotic cardiovascular disease, old myocardial infarction, heart failure, 
atherosclerosis severe, aortic aneurysm/dissection); peripheral vascular 
disease PVD (diabetic PVD, other aneurysm in lower extremities, PVD, foot 
wound complication, claudication intermittent, embolism/thrombosis (lower 
extremity), gangrene, gas gangrene, ulcer of lower limbs); metabolic 
(ketoacidosis , hyperosmolar, other coma). Apart from these clinical tags, 
hypertension, hyperlipidemia were also included in the analysis.  
The selection of these tags in the onset and “remission” cohort depended 
on the definition of the clinical tags. For example, clinical tags such as 
diabetic ophthalmologic disease (ICD 09 250.5x), Diabetic nephropathy (ICD-
9 250.4) were excluded in the onset cohort because these were included in 
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the definition of T2DM. Please see chapter 4 and chapter 5 for specific list of 
clinical conditions that were included in onset and “remission” study.  
b) Pharmacy: Oral diabetes drug, insulin, statin were identified using 
administrative pharmacy claims. The indicators were binary fields (Y/N). 
c) Demographic data: Age, gender, state, race were obtained from enrollment 
data. 
d) DCSI score: The DCSI score was calculated using methodology as 
described previously (98).  
Step 6: Data Transformation 
The final data was transformed to create an analytical dataset in a 
“counting process” input style as previously described (152, 153), where each 
observation represented a Medicare patient’s disease condition in a given year 
(Table 3.4).  
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Table 3.4: Sample dataset – counting process input style 
ID Year Start Stop T2DM Retinopathy Neuropathy xxx 
101 2008 0 1 1  (Y/N) - 2008  (Y/N) – 2008  (Y/N) - 2008 
101 2009 1 2 1  (Y/N) - 2009  (Y/N) – 2009  (Y/N) - 2009 
101 2010 2 3 1  (Y/N) - 2010  (Y/N) – 2010  (Y/N) - 2010 
101 2011 3 4 1  (Y/N) - 2011  (Y/N) – 2011  (Y/N) - 2011 
101 2012 4 5 0  (Y/N) - 2012  (Y/N) – 2012  (Y/N) - 2012 
101 2013 5 6 0  (Y/N) - 2013  (Y/N) – 2013  (Y/N) - 2013 
101 2014 6 7 0  (Y/N) - 2014  (Y/N) – 2014  (Y/N) - 2014 
101 2015 7 8 0  (Y/N) - 2015  (Y/N) – 2015  (Y/N) - 2015 
102 2008 0 1 1  (Y/N) - 2008  (Y/N) – 2008  (Y/N) - 2008 
102 2009 1 2 1  (Y/N) - 2009  (Y/N) – 2009  (Y/N) - 2009 
102 2010 2 3 1  (Y/N) - 2010  (Y/N) – 2010  (Y/N) - 2010 
102 2011 0 1 1  (Y/N) - 2011  (Y/N) – 2011  (Y/N) - 2011 
. . . . . . . . 
. . . . . . . . 
. . . . . . . . 
103 2011 0 1 1  (Y/N) - 2011  (Y/N) – 2011  (Y/N) - 2011 
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Table 3.5: Topics and example data elements included in the analytical data 
 Description Key data elements 
Clinical 
conditions 
Identified using medical and 
pharmacy claims 
Cardiovascular 
Cerebrovascular 
Peripheral Vascular Disease 
Retinopathy 
Metabolic 
Neuropathy 
Pharmacy Member’s drug usage based on 
their pharmacy claims 
Insulin 
Statin 
Enrollment Coverage with Managed Care 
Organization (MCO) 
Coverage indicators 
 
These variables were the key independent variables in the analysis (Table 
3.5). In the “remission” cohort analysis DCSI score was included. DCSI score 
was not included in the onset cohort analysis. 
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Statistical Analysis 
The data aggregation processes led to the creation of two separate 
analytical cohorts; a) onset b) “remission.” These cohorts were analyzed 
separately. The aggregated data was analyzed using the following statistical 
methods; 
a. Descriptive statistics:  Calculate means, frequencies. Descriptive 
statistics were used to generate member profile and rates. 
b. Survival analysis: Cox proportional hazard models. 
Cox proportional hazard models were specified to identify the significant 
variables associated with T2DM onset and “remission.” Statistical significance 
was assessed at α = 0.05. All variables were first included in the unadjusted 
model. The variables which are significant (p<0.05) were used in an adjusted 
model.  
Presentation of Statistical Results 
All results were reported in aggregated formats only. At no point were the 
individual or member level information/results reported. Any cells which 
contained less than 10 individuals were represented as “< 10.” No information is 
reported at a zip code level or by using specific service dates. This was a 
requirement from MCO, and helped in providing an additional layer of de-
identification. 
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Statistical Tools 
Hadoop (Scala, Spark 1.6) and SAS 9.2 were used for data processing 
and statistical analysis.  
Summary of methods 
This study used observational, descriptive, retrospective study using de-identified 
secondary administrative data. The data was analyzed using SAS and Hadoop 
and the results were presented in an aggregated format. 
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TYPE 2 DIABETES MELLITUS (T2DM) ONSET IN MEDICARE PATIENTS 65 
YEARS AND OLDER 
Short running title: T2DM Onset 
Type 2 Diabetes Mellitus (T2DM) is a chronic condition wherein the beta cells 
in the body do not produce enough insulin or the body does not use insulin well 
enough (also called insulin resistance), or there is complete absence of insulin 
production. T2DM is associated with deleterious macro- and microvascular 
outcomes (1) and is the seventh leading cause of death in the U.S. affecting 29.1 
million people (4). The total estimated national cost of diabetes in the U.S. in 
2012 was more than $245 billion, up from $174 billion in 2007 (5).  
T2DM can have a long asymptomatic phase i.e., an individual can sometimes 
be unaware that they have T2DM for 4 to 7 years before an actual diagnosis 
(15). The onset (or first occurrence of T2DM) is generally preceded by pre-
diabetes, a condition where an individual’s blood sugar is higher than normal, but 
not high enough to be classified as T2DM (54). Without intervention, pre-diabetes 
will progress to T2DM onset (55). When left unmanaged, T2DM continues to 
progress from onset to development of comorbidities and eventually lead to 
death. T2DM is a progressive disease. Since glucose is a continuous variable, 
the use of thresholds such as pre-diabetic or T2DM is somewhat arbitrary (64). 
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 Previous studies have identified several risk factors associated with T2DM 
onset such as: family history of T2DM; age; obesity; physical inactivity; prior 
history of gestational diabetes; impaired glucose tolerance; dipocytokines; 
inflammatory factors and hepatocyte factors; race/ethnicity; alcohol consumption; 
tobacco smoking; diet (6-8, 10, 11); high blood pressure (12); appendectomy 
(13); and hypothyroidism (14). However, there is still additional opportunity to 
further understand these and other factors that impact the onset of T2DM, 
especially in the Medicare patients 65 years and older.  
Understanding the impact of these comorbidities within the Medicare 
population is important because the Medicare population differs from the 
population at large in age, life expectancy, frequency of preexisting comorbid 
conditions and comorbidities due to progression of T2DM. These differences in 
turn affect the type of therapeutic and non-therapeutic interventions that are 
appropriate for this population (154). Understanding these factors will help design 
better T2DM prevention programs and thereby alleviate disease burden of T2DM 
and its comorbidities via proactive early intervention. This information will also be 
useful in cases where T2DM is identified later in its progression (due to late 
diagnosis) because improved glycemic control is still beneficial and improves 
quality of life (18).   
Research Design and Methods 
Study Design 
This retrospective study used de-identified administrative healthcare 
claims and enrollment data from a Medicare Advantage Prescription Drug 
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(MAPD) health plan offered by a large multistate healthcare company (a 
managed care organization, MCO). The data was collected during standard 
course of care. It was not originally collected for the purpose of this study, or any 
new study on human and animal subjects. Prior to the beginning of the study, this 
study protocol was reviewed and approved by the Institutional Review Board at 
University of Louisville. The study was also reviewed by the MCO’s privacy and 
ethics committee. 
Study Cohort 
Individuals may qualify for MAPD if they were at least 65 years of age in 
the year of their Medicare enrollment and met certain additional eligibility criteria. 
A smaller portion of individuals also qualified for MAPD for reasons such as 
disability or end stage renal disease (ESRD). Individuals whose initial eligibility 
criteria for enrollment into MAPD were due to disability or ESRD were excluded 
from this study.  
The large multistate healthcare company insured > 2.4 million individuals 
who had continuous MAPD coverage from January to December of 2015. Of 
these > 2.4 million individuals, there were more than 1.7 million individuals who 
had “age ≥ 65” as the original reason for Medicare entitlement. The rest qualified 
under Medicare disability or ESRD eligibility provisions and were excluded from 
this study. Of these 1.7 million individuals, there were 265,554 members who had 
continuous MAPD coverage with the MCO from January 2008 to December 
2015. Starting with the sampling frame of these 265,554 individuals, this study 
excluded the following during 2008 and 2015: a) individuals who had bariatric 
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surgery (including gastric bypass, laproscopic gastroenterostomy) (n = 619); b) 
individuals with polycystic ovary syndrome (n = 131) and lipodystrophy (n = 718) 
were excluded because these individuals may have medications which have 
competing indications with T2DM; c) individuals with any diagnostic codes 
related to nephropathy were excluded because a previous study published by 
Kaiser Permanente indicated that worsening renal function could lead to 
improved glycemic control (20). In the present study, chronic kidney disease 
(CKD) was excluded (n = 109,243) in order to identify a population without 
irreversible end organ damage. In the current study we excluded pre-existing 
nephropathy (41.3%) of the study sample. Previous research suggested the rate 
of CKD among individuals 65 years and older was 61% in a year. The CKD rate 
in the current study was likely lower because individuals with “disability” and 
“ESRD” as their initial reason for Medicare enrollment were excluded from the 
sampling frame (155);  d) individuals who had drug and/or steroid induced 
diabetes were excluded because the pathway for T2DM onset in these 
individuals may be different from normal pathways for T2DM onset (n = 3,436); e) 
individuals with type 1 diabetes (determined by ICD codes) were excluded 
because type 1 diabetes has a different etiology from T2DM (n = 25,535); f) 
individuals who had T2DM related diagnostics codes only during inpatient 
hospital stay and do not have T2DM diagnostic claims or T2DM related 
pharmacy claims in a non-hospital setting were excluded to account for potential 
surgery induced dysglycemia (n = 1,772); and, g) certain restricted groups as 
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required by the MCO’s privacy and legal agreements were also excluded from 
this study. The MCO’s IRB required this exclusion (n = 2,238). 
Inclusions 
To be included in T2DM onset cohort individuals were required to have no 
T2DM related claims in years 2008, 2009, 2010 and 2011 and have one of the 
following qualifiers: a) individuals who had no T2DM related claims in years 
2012, 2013, 2014 and 2015; or b) individuals who had T2DM onset in any year 
between 2012 and 2015. Upon onset, individuals were also required to have 
T2DM related claims every year until the end of the study (Appendix 4.1). 
After the above mentioned inclusion and exclusion criteria, the final T2DM 
onset cohort included 89,390 Medicare patients. 4,314 individuals had T2DM 
onset (T2DM onset group) and 85,076 individuals had no T2DM onset (no T2DM 
onset group) during the study period (Appendix 4.1). The baseline year was 
2011, since the entire study cohort had no T2DM in 2008, 2009, 2010 and 2011. 
Case definitions 
T2DM: T2DM individuals were identified using administrative medical and 
pharmacy claims data using the following criteria: a) at least two diagnoses of 
T2DM (International Classification of Diseases, Ninth Revision, Clinical 
Modification [ICD-9-CM] and/or (International Classification of Diseases, Tenth 
Revision, Clinical Modification [ICD-10-CM]; b) at least two pharmacy scripts 
related to T2DM; and, c) at least 2 claims (medical or pharmacy) related to 
T2DM. A minimum of two claims were used in the identification of T2DM as a 
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means of excluding patients who were potentially miscoded and patients who 
were suspected to have T2DM but were never formally diagnosed. 
Covariates: T2DM co-morbidities were defined using administrative claims data 
as described previously using both ICD-9 and ICD-10 diagnostic codes (98). The 
following co-morbidities were included in the study: a) retinopathy: other 
retinopathy, retinal edema, cystoid macular edema/degeneration (CSME), other 
retinal disorders, retinal detachment and blindness; b) neuropathy: amyotrophy, 
cranial nerve palsy, neurogenic bladder, gastroparesis/diarrhea and orthostatic 
hypotension; c) cerebrovascular: transient ischemic attack, stroke; d) 
cardiovascular diseases: atherosclerosis, other ischemic heart disease (IHD), 
angina pectoris, other chronic IHD, myocardial infarction, ventricular fibrillation 
and arrest, atrial fibrillation, arrest, other atherosclerotic cardiovascular disease, 
old myocardial infarction, heart failure, atherosclerosis severe, and aortic 
aneurysm/dissection; e) peripheral vascular disease (PVD): other aneurysm of 
lower extremities, foot wound and complications, embolism/thrombosis in lower 
extremities, ulcer of lower limbs; f) hypertension; and g) hyperlipidemia. 
Demographic information (age, gender, and race) was based on 
enrollment data. T2DM related pharmacy and statin use were determined using 
administrative pharmacy data.   
Statistical Analysis 
Data aggregation and the implementation of inclusions and exclusions 
was done in Hadoop (using Spark, Scala and Hive). Hadoop is an open source 
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software framework for distributed processing and distributed storage of very 
large datasets (151). The processing was done in Hadoop because of the 
volume of the data which included ≥ 2.4 million individuals’ medical and 
pharmacy claims data from 2008 to 2015. Means and frequencies to generate 
member profiles was calculated using Hadoop. The analytical dataset was 
created in a counting process input style (152, 153). This data was then moved 
into SAS 9.2. (SAS Institute Inc., Cary NC) to calculate rate of T2DM onset. Cox 
proportional hazard models were specified to identify the significant variables 
associated with T2DM onset. SAS procedure PROC PHREG was used for Cox 
proportional hazard models (152). 
The unadjusted model was developed using demographic, pharmacy, and 
clinical conditions. The level of significance for unadjusted models was p<0.05. 
The model was developed using Cox proportional hazard. Variables that were 
significant in the unadjusted model were then included in the adjusted model. In 
the final analysis, the adjusted model included the demographic variables 
(gender and race), pharmacy (statin use) and clinical conditions (hypertension, 
hyperlipidemia, heart failure, ulcer of lower limbs, atherosclerosis, retinal edema, 
gastroparesis, orthostatic hypotension, cerebrovascular, atherosclerosis, other 
ischemic heart disease (IHD), other chronic IHD, myocardial infarction (MI), 
ventricular fibrillation and arrest, other atherosclerotic cardiovascular disease 
(ASCVD), old MI, atherosclerosis severe, embolism, blindness and low vision, 
other retinopathy and angina pectoris ). The level of significance for all statistical 
tests was p< 0.05.  
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Results 
There were 89,390 Medicare patients 65 years and older who did not have 
T2DM in 2008, 2009, 2010 and 2011. Of these, 4,314 Medicare patients were 
diagnosed with T2DM between 2012 and 2015, while the remaining 85,076 
Medicare patients continued to have no T2DM diagnosis until the end of study, 
i.e., 2015. The cumulative rate of diagnosed T2DM onset in the study cohort was 
4.82% (4314/89,390) (Table 4.1). The rates of diagnosed T2DM were 0.82%, 
0.88%, 1.04% and 2.09% in years 2012, 2013, 2014 and 2015, respectively. 
 In the baseline year (2011), the average age of Medicare patients in the 
T2DM onset cohort (n = 4,314) was 72.1 years compared to the average age of 
73.0 years for the no-onset cohort (n=85,076) (p<0.0001). The T2DM onset 
cohort consisted of 60.3% females compared to 63.5% females in the no-onset 
cohort (Table 4.1) (p<0.0001). Even though the difference in the gender (3.2%) 
and age (1.9 years) are statistically significant, these groups are not very 
significant from each other from a theoretical perspective (Table 4.1). 
At baseline there were significantly more non-white (African American, 
Hispanic) individuals (19.5%) in the T2DM onset cohort compared to the T2DM 
no onset cohort (11.7%) (p<0.0001) (Table 4.1). 
At baseline, the T2DM onset cohort had significantly higher prevalence of 
disease conditions compared to no-onset cohort. Individuals in the T2DM onset 
cohort had higher prevalence of clinical conditions such as hypertension (70.1% 
vs. 59.1%), hyperlipidemia (69.4% vs. 59.5%), cardiovascular (atherosclerosis 
(5.0% vs. 7.2%), other ischemic heart disease (0.8% vs 1.5%), angina pectoris 
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(2.1% vs. 3.6%), other chronic ischemic heart disease (12.3% vs. 15.4%), other 
atherosclerotic cardiovascular disease (0.9% vs. 1.3%), history of myocardial 
infarction (3.2% vs. 4.6%), heart failure (3.1% vs. 4.8%)), (p< 0.05) (Table 4.2). 
Even though the clinical conditions related to cardio vascular disease were 
significant, they might not be a clinically significant difference (Table 4.2). 
In bivariate and multivariate analysis, male gender, non-white (African 
American, Hispanic), statin use, hypertension, hyperlipidemia, heart failure, ulcer 
of lower limbs, atherosclerosis, other retinopathy, angina pectoris, blindness and 
low vision, absence of other ischemic heart disease (IHD)  was associated with 
T2DM onset in Medicare patients (p<0.05) (Figure 4.1, Figure 4.2 and Appendix 
4.2). 
Conclusions 
The four year rate of T2DM onset was 48.2 per 1000 population. The 
average rate of T2DM onset was 12.05 per 1000 per year. This rate was 
consistent with the unadjusted incidence of T2DM of 11.5 per 1000 in the U.S. 65 
years or older population (4).  
Previously published research has documented some of the risk factors 
for T2DM on: family history of T2DM, age, obesity, and physical inactivity, prior 
history of gestational diabetes race, alcohol consumption, tobacco smoking, diet 
(6-8, 10, 11). Some of the known risk factors that characterize metabolic 
syndrome, a precursor for T2DM: impaired glucose tolerance; dipocytokines; 
inflammatory factors and hepatocyte factors; and hypertension (12, 156). 
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Gender and Race: The study presented here found that males, non-white 
(African American, Hispanic) are significantly associated with T2DM onset in the 
Medicare patients. Male gender was more likely to be associated with T2DM 
onset compared to female gender (p<0.0001). Previous studies found globally 
that males are more likely to develop T2DM than females (157, 158). This trend 
has changed over the last 50 years. Females were more likely to have diagnosed 
T2DM, but in recent years, the increasing sedentary lifestyles and diets of males 
appears to be associated with increased prevalence of T2DM (159, 160). 
Consistent with prior studies, the current investigation found that African 
Americans and Hispanics were more likely to have an onset of T2DM than 
Caucasians in the Medicare population (161). These findings further emphasize 
the need for culturally sensitive interventions to help ameliorate racial disparities 
of T2DM onset especially in the elderly, sedentary population. 
Statins: This study also evaluated the role of statin use on T2DM onset. The 
HMG-CoA inhibitors (statins), are one of the most commonly prescribed drugs 
worldwide to reduce cholesterol, and prevent or manage coronary heart disease 
(162). In a meta-analysis of 13 randomized trials, the use of statins was 
associated with a 9% increase in the risk of T2DM onset, with the risk being the 
highest in the older population. However, considering its effect on reducing 
coronary events, previous studies have recommended no change in clinical 
decision making for medium to high risk of cardiovascular diseases (163). Similar 
to prior studies, the present investigation found that statin use was associated 
with the onset of T2DM in Medicare patients (p<0.0001) and recommend 
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surveillance of dysglycaemia among non-T2DM Medicare patients who are 
receiving statin treatment.  
Hypertension: High blood pressure affects approximately a billion people 
worldwide and is a common yet modifiable risk factor for T2DM onset. Individuals 
who have hypertension are 2.5 times more likely to develop T2DM (164, 165). In 
the present study, hypertension is associated with T2DM onset (p<0.05). 
Retinopathy: Prior investigations suggest that nearly 21% of individuals who are 
diagnosed with T2DM also have some level of retinopathy at the time of 
diagnosis (166). In individuals who do not have T2DM related retinopathy, the 
symptoms are generally a manifestation of either retinal micro aneurysms or blot 
hemorrhages. Advanced age and hypertension are associated with the 
development of non-diabetic retinopathy but hypertension and T2DM are risk 
factors for retinopathy in individuals who are < 65 years of age years (167).  
The present study found that retinopathy (other retinopathy, blindness or 
low vision) was associated with T2DM onset in Medicare patients (p<0.05). One 
possible explanation is that when an optometrist or other provider evaluates a 
Medicare individual for non-diabetic retinopathy, they might recommend T2DM 
screening. This interaction with their provider and subsequent evaluation of blood 
glucose can lead to diagnosis of T2DM. 
Hyperlipidemia: Hyperlipidemia is key component of metabolic syndrome. 
Metabolic syndrome refers to the co-occurrence of several known cardiovascular 
risk factors such as atherogenic dyslipidemia (elevated triglycerides and low 
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high-density lipoprotein [HDL]), high blood pressures, elevated glucose levels, 
and abdominal obesity with pro-thrombotic and pro-inflammatory states (168). 
These conditions have a common pathway and are interrelated. Individuals with 
metabolic syndrome are at a significantly higher risk of developing T2DM (169). 
In the study presented here, hyperlipidemia was associated with T2DM onset in 
the Medicare patients (p<0.05).  Hyperlipidemia and hypertension are significant 
predictors of T2DM onset, and may be a proxy for metabolic syndrome as a 
predictor for T2DM onset (170).   
Peripheral vascular disease (PVD): PVD is characterized by vascular smooth 
muscle cell dysfunction, endothelial dysfunction, inflammation and 
hypercoagulability. PVD is a frequent comorbidity in T2DM. Vascular ulcers such 
as ulcers of lower limbs are a common cause for older patients to visit a provider 
(171). In the study presented here non-diabetic ulcer of lower limbs was 
associated with T2DM onset in Medicare patients (p<0.05).  
Cardiovascular disease (CVD): As previously mentioned above, metabolic 
syndrome is characterized by clustering of risk factors such as prothrombotic, 
hypertension and dyslipidemia. Metabolic syndrome independently contributes to 
CVD and T2DM (172). This study evaluated several cardiovascular conditions 
associated with T2DM: angina pectoris, atherosclerosis, heart failure, other 
chronic IHD. Clinical and lab data related to metabolic syndrome was not 
available, to further evaluate if the observed associations are due to the 
underlying metabolic syndrome. Despite this limitation, these finding can still 
provide valuable information to providers about the prognosis of the T2DM. 
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Some of the cardiovascular conditions that were significantly associated with 
T2DM were: a) angina pectoris: angina pectoris (angina) is characterized by 
chest pain or discomfort, often associated with myocardial ischemia, arterial 
insufficiency or hypoxia. Angina is generally a symptom for an underlying cause 
such as coronary artery disease (173). Angina pectoris is associated with T2DM 
onset in the present study (p<0.05). Associations found with angina and T2DM 
onset must be re-evaluated by looking at the underlying causes; b) other chronic 
IHD: this diagnostic code is associated with loss of elasticity and thickening of the 
coronary arteries, leading to progressive arterial insufficiency. This study found 
that in bivariate analysis other chronic IHD was associated with T2DM onset. 
However when adjusted for other factors IHD had a protective effect on T2DM 
onset. This finding suggests that individuals who have hypertension and 
hyperlipidemia and also have IHD might have different behavior towards their 
health and hence might be able to delay onset of T2DM (174).; c) heart failure 
and atherosclerosis were associated with T2DM onset in Medicare patients. 
In summary, male gender, non-white ethnicity (African American, 
Hispanics), statin use, hypertension, hyperlipidemia, heart failure, ulcer of lower 
limbs, atherosclerosis, other retinopathy, angina pectoris, blindness and low 
vision, absence of other chronic ischemic heart disease (IHD) was associated 
with T2DM onset in Medicare patients. African American and Hispanics (without 
regard to gender), statins, hyperlipidemia, and hypertension are findings in 
agreement with previously reported risk factors with development of T2DM. The 
new associations with T2DM discovered in this investigation include: heart 
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failure, ulcer of lower limbs, atherosclerosis, other retinopathy, angina pectoris, 
blindness and low vision, and absence of other chronic ischemic heart disease 
(IHD).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The tables and figures are placed at the end of the article as per the 
requirement of the journal.  
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Tables and Figure Legends 
 
Table 4.1: Baseline demographic and T2DM onset characteristics 
Characteristic  
No Onset* 
(n = 85,076) 
Onset ** 
(n = 4,314) P value  
Age, mean (SD), years 73.0 (5.6) 72.1 (5.1) <.0001 
Female sex 63.5% 60.3% <.0001 
Race/ethnicity     <.0001 
White 75,051 (88.3) 3,465 (80.5)   
Black 6,316 (7.4) 542 (12.5)   
Others 3,640 (4.3) 300 (7.0)   
 
Data are represented as n (%). 
*Missing data in no onset cohort: race (n = 69).  
**Missing data in onset cohort: race (n = 7).   
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Table 4.2: Baseline comorbidities 
Characteristic  
No Onset 
(n = 85,076) 
Onset 
(n = 4,314) P value  
Hypertension 50,336 (59.2) 3,024 (70.1) <.0001 
Hyperlipidemia 50,636 (59.5) 2,993 (69.4) <.0001 
Retinopathy       
Other retinopathy 795 (0.9) 42 (1.0) 0.7950 
Retinal edema 351 (0.4) 15 (0.3) 0.5150 
CSME 430 (0.5) 26 (0.6) 0.3820 
Other retinal disorders 294 (0.3) 10 (0.2) 0.2100 
Retinal detachment 647 (0.8) 37 (0.9) 0.4750 
Blindness 535 (0.6) 32 (0.7) 0.3620 
Neuropathy       
Neurogenic bladder 154 (0.2) <10 0.7770 
Gastroparesis/diarrhea 174 (0.2) 12 (0.3) 0.3000 
Orthostatic hypotension 1,226 (1.4) 57 (1.3) 0.5190 
Cerebrovascular       
TIA 1,486 (1.7) 78 (1.8) 0.7640 
Stroke 5,104 (6.0) 288 (6.7) 0.0690 
Cardiovascular       
Atherosclerosis 4,216 (5.0) 311 (7.2) <.0001 
Other IHD 675 (0.8) 66 (1.5) <.0001 
Angina pectoris 1,773 (2.1) 155 (3.6) <.0001 
Other chronic IHD 10,445 (12.3) 664 (15.4) <.0001 
Myocardial infarction 588 (0.7) 37 (0.9) 0.2000 
Ventricular fibrillation, arrest 5,508 (6.5) 308 (7.1) 0.0840 
Atrial fibrillation, arrest 78 (0.1) <10 0.3220 
Other ASCVD 761 (0.9) 55 (1.3) 0.0100 
Old myocardial infarction 2,761 (3.2) 197 (4.6) <.0001 
Heart failure 2,673 (3.1) 208 (4.8) <.0001 
Atherosclerosis, severe 38 (0.0) <10 0.9590 
Aortic aneurysm/dissection 1,307 (1.5) 52 (1.2) 0.0830 
Peripheral vascular disease       
Other aneurysm, LE 35 (0.0) <10 0.3770 
Foot wound + complication 26 (0.0) <10 0.7860 
Embolism/thrombosis (LE) 75 (0.1) <10 0.5520 
Ulcer of lower limbs 493 (0.6) 22 (0.5) 0.5560 
 
Data are expressed as n (%). Baseline year = 2011. 
IHD, ischemic heart disease; LE, lower extremity; TIA, transient ischemic attack; 
ASCVD, atherosclerotic cardiovascular disease 
 
 58   
 
           Figure 4.1: Unadjusted Cox proportional hazard for T2DM onset 
 
 
MI, Myocardial infarction; ASCVD, atherosclerotic cardiovascular disease; IHD, 
ischemic heart disease; Race other, non-white and non-African American. 
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           Figure 4.2: Adjusted Cox proportional hazard for T2DM onset 
 
 
IHD, ischemic heart disease; Race other, non-white and non-African American. 
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Appendix 4.1: T2DM Onset 
T2DM Diagnosis   
2008§ 2009 2010 2011 2012 2013 2014 2015 PATTERN§§ Description 
NO NO NO NO NO NO NO NO 00000000 
No onset  
( n = 85,076) 
NO NO NO NO NO NO NO YES 00000001  
NO NO NO NO NO NO YES YES 00000011 Onset 
NO NO NO NO NO YES YES YES 00000111 (n = 4,314) 
NO NO NO NO YES YES YES YES 00001111   
NO NO NO YES YES YES YES YES 00011111 Onset  
NO NO YES YES YES YES YES YES 00111111 (excluded) 
NO YES YES YES YES YES YES YES 01111111   
NO NO NO NO NO NO YES NO 00000010 
No continuous onset  
(excluded) NO NO NO NO NO YES NO YES 00000101 
§NO = no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis 
§§0 = no T2DM and 1 = presence of T2DM
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Appendix 4.2: Unadjusted and adjusted Cox proportional hazard for T2DM onset 
 
 
  Any onset (n = 4,314)   
  Hazard Ratio (95% CI)   
Characteristic n (%) Unadjusted P Value Fully adjusted P value 
Sex           
Men  1,711 (5.2) 1.0 (ref) <0.0001  1.0 (ref) <0.0001  
Women  2,603 (4.6) 0.83 (0.79 - 0.86)    0.79 (0.76 - 0.83)   
Race           
White  3,465 (4.4) 1.0 (ref) <0.0001  1.0 (ref) <0.0001  
African American  542 (7.9) 1.86 (1.75 - 1.98)    1.76 (1.65 - 1.88)   
Other  300 (7.6) 1.75 (1.61 - 1.89)    1.66 (1.53 - 1.81)   
Statins           
No statins  2,228 (4.2) 1.0 (ref) <0.0001  1.0 (ref) <0.0001  
Statins  2,086 (5.7) 2.04 (1.96 - 2.13)    1.28 (1.22 - 1.35)   
Clinical Conditions           
No hypertension 1,290 (3.6) 1.0 (ref)  <0.0001 1.0 (ref)  <0.0001 
Hypertension  3,024 (5.7) 2.91 (2.75 - 3.08)    2.12 (1.99 - 2.25)   
No hyperlipidemia 1,321 (3.7) 1.0 (ref) <0.0001  1.0 (ref)  <0.0001 
Hyperlipidemia  2,993 (5.6) 2.85 (2.69 - 3.01)    1.99 (1.88 - 2.12)   
Retinopathy           
No other retinopathy  4,272 (4.8) 1.0 (ref) <0.0001  1.0 (ref)  0.0024 
Other retinopathy  42 (5.0) 1.51 (1.29 - 1.77)    1.27 (1.09 - 1.49)   
No retinal edema  4,299 (4.8) 1.0 (ref)  0.0303 1.0 (ref)  0.1604 
Retinal edema  15 (4.1) 1.31 (1.03 - 1.67)    1.19 (0.93 - 1.53)   
No blindness or low 
vision  4,282 (4.8) 1.0 (ref) <0.0001  1.0 (ref)  0.0194 
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  Any onset (n = 4,314)   
  Hazard Ratio (95% CI)   
Characteristic n (%) Unadjusted P Value Fully adjusted P value 
Blindness or low vision  32 (5.6) 1.45 (1.22 - 1.73)   1.23 (1.03 - 1.47)    
 
Neuropathy      
No gastroparesis  4,302 (4.8) 1.0 (ref) 0.0193  1.0 (ref) 0.0641  
Gastroparesis  12 (6.5) 1.56 (1.07 - 2.26)    1.42 (0.98 - 2.06)   
       No orthostatic 
hypotension  4,257 (4.8) 1.0 (ref) 0.0007  1.0 (ref) 0.8693  
       Orthostatic hypotension  57 (4.4) 1.24 (1.09 - 1.39)    0.99 (0.87 - 1.12)   
No cerebrovascular 3,992 (4.8)  1.0 (ref) <0.0001  1.0 (ref) 0.7160  
Cerebrovascular  322 (5.2) 1.33 (1.25 - 1.42)    0.99 (0.92 - 1.06)   
Cardiovascular           
No atherosclerosis  4,003 (4.7) 1.0 (ref)  <0.0001 1.0 (ref)  <.0001 
Atherosclerosis  311 (6.9) 1.71 (1.61 - 1.81)    1.31 (1.23 - 1.39)   
No other IHD  4,248 (4.8) 1.0 (ref)  <0.0001 1.0 (ref)  0.1124 
Other IHD  66 (8.9) 1.83 (1.54 - 2.17)    1.16 (0.97 - 1.39)   
No angina pectoris 4,159 (4.8) 1.0 (ref)  <0.0001 1.0 (ref) <.0001  
Angina pectoris  155 (8.0) 1.83 (1.67 - 2.02)    1.23 (1.11 - 1.37)   
No other chronic 
IHD  3,650 (4.7) 1.0 (ref) <0.0001  1.0 (ref)  <.0001 
Other chronic IHD  664 (6.0) 1.43 (1.35 - 1.50)    0.85 (0.79 - 0.91)   
No myocardial 
infarction  4,277 (4.8) 1.0 (ref) <0.0001  1.0 (ref)  0.2523 
Myocardial 
infarction  37 (5.9) 1.66 (1.42 - 1.95)    1.10 (0.93 - 1.30)   
No ventricular 
fibrillation, arrest  4,006 (4.8) 1.0 (ref)  <0.0001 1.0 (ref) 0.3138  
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  Any onset (n = 4,314)   
  Hazard Ratio (95% CI)   
Characteristic n (%) Unadjusted P Value Fully adjusted P value 
Ventricular 
fibrillation, arrest  308 (5.3) 1.25 (1.17 - 1.33)    0.97 (0.90 - 1.03)   
No other ASCVD  4,259 (4.8) 1.0 (ref)  <0.0001 1.0 (ref) 0.7064  
Other ASCVD  55 (6.7) 1.46 (1.34 - 1.60)    1.02 (0.92 - 1.13)   
No old myocardial 
infarction  4,117 (4.8) 1.0 (ref) <0.0001  1.0 (ref) 0.7608  
Old myocardial 
infarction  197 (6.7) 1.55 (1.42 - 1.70)    1.02 (0.92 - 1.13)   
No heart Failure 4,106 (4.7)  1.0 (ref) <0.0001  1.0 (ref) <.0001  
Heart Failure  208 (7.2) 1.81 (1.69 - 1.95)    1.42 (1.32 - 1.54)   
No Atherosclerosis 
severe  (4.8) 1.0 (ref) <0.0293  1.0 (ref) 0.4515  
Atherosclerosis 
severe  < 10 (5.0) 1.76 (1.06 - 2.91)    0.81 (0.48 - 1.39)   
PVD           
No embolism  (4.8) 1.0 (ref)  0.0002  1.0 (ref) 0.2633  
Embolism  <10 (6.3) 2.06 (1.41 - 3.00)    1.25 (0.85 - 1.83)   
No ulcer of lower 
limbs  4,292 (4.8) 1.0 (ref)  <0.0001 1.0 (ref) 0.0012  
Ulcer of lower 
limbs  22 (4.3) 1.57 (1.30 - 1.89)    1.38 (1.14 - 1.67)   
 
Fully adjusted model includes all variables in this table. Data represented as n (%) for baseline year (2011) 
*Missing data in No Onset cohort: race (n = 69). **Missing data in Onset cohort: race (n = 7).
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TYPE 2 DIABETES MELLITUS (T2DM) “REMISSION” IN MEDICARE 
PATIENTS 65 YEARS AND OLDER WITHOUT BARIATRIC SURGERY 
SHORT RUNNING TITLE: T2DM “REMISSION” 
Type 2 diabetes mellitus (T2DM) is generally considered as a chronic, 
incurable, progressive and life-long disease condition. T2DM disease 
management focuses primarily on glycemic control and management of the 
macro- and microvascular complications that may be associated with 
hyperglycemia (175, 176). However, a growing body of evidence indicates that 
T2DM remission can be achieved in certain individuals (107).  
The American Diabetes Association (ADA) has defined the term remission 
as “…achieving glycaemia below the diabetic range in the absence of active 
pharmacologic or surgical therapy.”  ADA classifies remission into one of the 
following three types: a) partial remission, defined as sub-diabetic hyperglycemia 
without active pharmacologic therapy or ongoing procedures for at least 1 year. 
Sub-diabetic hyperglycemia is characterized by HbA1c < 6.5% and/or fasting 
glucose 100–125 mg/dL [5.6–6.9 mmol/l]; b) complete remission, defined as 
“normal” measures of glucose metabolism without active pharmacologic therapy 
or ongoing procedures for at least 1 year. Normal measure of glucose 
metabolism is when HbA1c is in the normal range, < 5.7%, <39 mmol/mol, fasting 
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glucose <100 mg/dL [5.6 mmol/l]); and c) prolonged remission, defined as 
complete remission for at least 5 years (106).  
Current evidence on T2DM remission suggests that there are at least two 
key approaches for T2DM remission namely, metabolic/bariatric surgery and/or 
intensive lifestyle management (175). Of these two approaches, bariatric 
(“weight-loss”) surgery has been proved to be effective in treating T2DM patients 
whose BMI is 35 kg/m2 or higher (130) with a success of achieving T2DM 
remission between 24% and 95% (131, 132). Bariatric surgery is considered 
relatively safe with 30 day mortality between 0.1% and 1.1%. However, the risk 
of developing acute complications and long term complications is high (17%). 
The rate of reoperation following bariatric surgery is around 7% and patients are 
often required to have a close postoperative medical monitoring (177-180).   
Current understanding of T2DM remission among non-bariatric patients 
intervention is very limited. A recent post hoc randomized controlled study from 
the Look AHEAD (Action for Health for Diabetes) and the 2014 Kaiser 
Permanente study have shown metabolic/bariatric surgery is not the only 
pathway to remission. Although rare, T2DM remission does occur in certain 
populations without bariatric surgery (19, 20, 107). However, very little is known 
about remission and factors associated with it.  
Understanding factors predictive of remission within the Medicare patients 65 
years and older is important because Medicare population differs from population 
at large by their age, life expectancy, and frequency of comorbidities (154), and 
have a significantly higher prevalence of T2DM compared to the population at 
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large (181). Therefore, understanding these factors have substantial clinical 
relevance to the design of interventions which lead to remission. In addition, 
these data could be used to help design better T2DM management programs.  
In order to identify remission as per the ADA definition, a researcher would 
need both pharmacy and laboratory data (HbA1c). However, laboratory test data 
are not always available to researchers, especially to those researchers who only 
rely on administrative claims data for their analytical work (99). Therefore, a 
modified definition for remission is offered in the present study. In this 
investigation, the modified definition of remission is enclosed in quotation marks 
(as “remission”).  
In summary, this study was conducted to estimate the rate of type 2 diabetes 
mellitus (T2DM) “remission” and to identify the factors that are associated with 
T2DM “remission” in Medicare patients 65 years and older who did not undergo 
bariatric surgery using administrative healthcare claims data in the absence of 
HbA1c data. 
Research Design and Methods 
Study Design 
This study was a retrospective cohort analysis using Medicare Advantage 
Prescription Drug (MAPD) health plan data. This administrative data includes 
member level enrollment, medical claims and pharmacy claims data. These data 
were collected during the standard course of care. It was not originally collected 
for the purpose of research or any new study of human or animal subjects. Prior 
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to the start of the study this study protocol was reviewed and approved by the 
University of Louisville Institutional Review Board. The study was also approved 
by the MCO’s review board. 
Study Cohort 
The federal government offers original Medicare insurance, which includes 
Medicare Part A (Hospital Insurance) and Medicare Part B (Medical Insurance). 
Part C (or Medicare advantage) are offered through private insurance 
companies. Part C includes the benefits of Part A, Part B and sometimes the 
optional Part D (prescription drug coverage) along with several choices of 
programs and services specific to each Managed Care Organization (MCO). 
Individuals can only be enrolled in Part C if they qualify for Medicare part A and 
part B. An individual may qualify for Medicare if they are at least 65 years old in 
the year of their Medicare enrollment and meet certain additional eligibility 
criteria. In addition, some individuals may qualify for Medicare for other reasons 
such as disabilities or end stage renal disease (ESRD). Individuals whose initial 
reason for Medicare enrollment was either disability or ESRD were excluded 
from the present study. 
The large multistate MCO offers Medicare Advantage Prescription Drug 
Plan (MAPD) a Part C plan, which includes the benefits of Medicare Part A, Part 
B and Part D, to individuals. The MCO insured more than 2.4 million individuals 
who had continuous MAPD coverage from January 1, 2008 to December 31, 
2015. Of these ≥ 2.4 million individual more than 1.7 million MAPD individuals 
had “age ≥ 65” as the original reason for Medicare enrollment. The remainder 
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qualified under Medicare disability or ESRD eligibility provisions. Of these > 1.7 
million members there were 265,554 members who had continuous MAPD 
coverage with the MCO from January 2008 to December 2015.  
The initial sample after the above exclusions of 265,554 members, 
additional exclusions were: a) individuals who had a prior bariatric surgery 
(including gastric bypass, laparoscopic gastroenterostomy) (n = 619); b) 
individuals with polycystic ovary syndrome (n = 131), and lipodystrophy (n = 
718); c) individuals with any diagnostic codes related to nephropathy were 
excluded because it indicates irreversible end organ damage. In the current 
study, the nephropathy exclusion resulted in excluding 41.3% of the study 
sample. Previous research suggested that the rate of chronic kidney disease 
(CKD) in individuals who are 65 years and older was 61%. CKD rate in the 
current study was likely lower because individuals with “disability” and “ESRD” as 
their initial reason for Medicare enrollment were excluded from the sample (155); 
d) individuals who had pharmacy claims related to drug and/or steroid induced 
diabetes were excluded (n = 3,436); e) individuals with type 1 diabetes were 
identified using ICD codes and excluded because type 1 diabetes has a different 
etiology from T2DM (n = 25,535); f) individuals who had T2DM related 
diagnostics codes only during inpatient hospital stay and did not have T2DM 
diagnostic claims or T2DM related pharmacy claims in a non-hospital setting 
were excluded to account for potential surgery induced dysglycemia (n = 1,772); 
g) certain restricted groups as required by the MCO’s privacy and legal 
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agreements  were also excluded from this study. The MCO’s IRB required this 
exclusion (n = 2,238). 
The definition of “remission” in this study was different from that used by 
ADA, because of the lack of HbA1c data. An individual was encoded as being in 
“remission” if they met the following criteria: a) had two or more T2DM related 
claims in previous years; b) had no T2DM related claims in the given year; c) 
upon “remission” T2DM individuals were required to continue to have no T2DM 
related claims until the end of study period, 2015. This requirement excluded 
individuals who experienced T2DM relapse. This study’s focus was only on 
individuals who experienced continued “remission” and not intermittent 
“remission.”   
Individuals were required to have T2DM in the year 2008, 2009, 2010 and 
2011 and either continue to be diabetic (no “remission” group) or achieve 
“remission” (the “remission” group) to be included in the T2DM “remission” study 
cohort. T2DM relapse can happen in some individuals after “remission.” 
Individuals who had relapse after first “remission” were excluded from the study. 
The final population included a total of 10,059. The “remission” group included 
500 individuals and 9,559 patients in the no “remission group. Since the entire 
study cohort had T2DM in 2008, 2009, 2010 and 2011, the baseline year was 
2011 (Appendix 5.1). 
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Case definitions 
T2DM: T2DM individuals were identified using administrative medical and 
pharmacy claims with the following criteria: at least two diagnoses of T2DM 
(International Classification of Diseases, Ninth Revision, Clinical Modification 
[ICD-9-CM] and/or (International Classification of Diseases, Tenth Revision, 
Clinical Modification [ICD-10-CM]; at least two pharmacy prescriptions related to 
T2DM; at least 2 claims (medical or pharmacy) related to T2DM. A minimum of 
two claims was used in the identification of T2DM to exclude patients who were 
miscoded and patients who were suspected to have T2DM but were never 
formally diagnosed. 
DCSI: The Diabetes Complications Severity Index (DCSI) models the severity of 
diabetes complication at a specific point in the patient’s life. DCSI is calculated as 
previously described (98, 99). The final output is a patient’s score (or index 
value) with a range from 0 to 13. An individual with DCSI score of 0 indicates the 
patient has the least severe diabetes. This DCSI score can be used to group the 
members into high, medium and low diabetic severity. 
Retinopathy: This study used ICD-9 and ICD-10 diagnostic codes to identify 
diabetic ophthalmologic disease, background retinopathy, other retinopathy, 
retinal edema, cystoid macular edema/degeneration (CSME), other retinal 
disorders, proliferative retinopathy, retinal detachment, blindness, vitreous 
hemorrhage). An individual with any of the above clinical conditions was encoded 
as having retinopathy.  
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Neuropathy: This study used ICD-9 and ICD-10 diagnostic codes to identify 
diabetic neuropathy, amyotrophy, cranial nerve palsy, mononeuropathy, 
Charcot’s arthropathy, polyneuropathy, neurogenic bladder, autonomic 
neuropathy, gastroparesis/diarrhea, orthostatic hypotension. An individual with 
any of the above clinical conditions was encoded as having neuropathy.  
Peripheral Vascular Disease (PVD): This study used ICD-9 and ICD-10 
diagnostic codes to identify diabetic PVD, other aneurysm lower extremities, 
PVD, foot wound and complication, claudication, intermittent, 
embolism/thrombosis lower extremities, gangrene, gas gangrene, ulcer of lower 
limbs. An individual with any of these clinical conditions was encoded as having 
PVD. 
Covariates 
T2DM related clinical conditions were defined using administrative claims 
data as described previously using both ICD-9 and ICD-10 codes, where 
applicable (98). Demographic information (age, gender and race) was based on 
enrollment data. T2DM related pharmacy and statins use was determined using 
administrative pharmacy claims data.   
Statistical Analysis 
Enrollment, medical and pharmacy claims data from 2008 to 2015 of more 
than 2.4 million members were included in the data aggregation. The data 
aggregation was done in Hadoop (using Spark, Scala and Hive). Hadoop is an 
open source software framework for distributed processing and distributed 
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storage of very large datasets (151). Processing was done in Hadoop because of 
the volume of the data included. The analytical dataset was created in a counting 
process input style (152, 153) Means and frequencies to generate member 
profile were calculated in Hadoop. This data was then moved into SAS 9.2. (SAS 
Institute Inc., Cary NC) to calculate rate for T2DM “remission.” Cox proportional 
hazard models were specified to identify the significant variables associated with 
T2DM “remission.” SAS procedure PROC PHREG was used for Cox proportional 
hazard models (152). The adjusted model included demographic variables 
(gender, and race), statin use, clinical conditions (hypertension, hyperlipidemia, 
retinopathy, neuropathy, other chronic ischemic heart disease, other 
atherosclerotic cardiovascular disease and peripheral vascular disease) and 
DCSI score. The level of significance for all statistical tests was p < 0.05.  
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Results 
There were 10,059 MAPD individuals who had T2DM in 2008, 2009, 2010 
and 2011. In the study period there were 4.97% (95% CI, 3.05% - 8.00%) 
Medicare patients 65 years and older (n=500) who met the definition of T2DM 
“remission” in the study cohort. At 2011, the baseline year, the average age of 
the “remission” group was 73.7 years, while that of the non- “remission” group 
was 72.6 years. In the “remission” group 62.2% were female, compared to 57.2% 
in the non-“remission” group. 63.6% of the “remission” group did not use any 
diabetes-related medications prior to going into “remission (Table 5.1). 
At baseline, the T2DM “remission” group had significantly lower disease 
prevalence of hypertension, hyperlipidemia, retinopathy (overall, diabetic 
ophthalmologic disease, background retinopathy, retinal edema, and blindness), 
neuropathy (overall, diabetic neuropathy, polyneuropathy) and diabetic peripheral 
vascular disease. However, the “remission” group had higher cardiovascular 
disease (overall, myocardial infarction, aortic aneurysm and dissection) (p<0.05) 
(Table 5.2). 
In bivariate and multivariate analyses, T2DM “remission” was associated 
with no statin use, low diabetes complications severity index score, no 
hypertension, no hyperlipidemia, no neuropathy, no retinopathy, race 
(Asian/Hispanic), other chronic ischemic heart disease (IHD) and female gender 
(p<0.05). 
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In bivariate analysis “remission” was associated with ulcer of lower limbs 
and peripheral vascular disease (PVD). However, these associations were 
attenuated in multivariate analyses and were not significant (p>0.05) (Figure 5.1, 
Figure 5.2 and Appendix 5.2).  
Conclusions 
In Medicare patients 65 years and older, T2DM “remission” does occur 
without bariatric surgery. 4.97% (95% CI, 3.05% - 8.00%) of Medicare patients 
65 years and older met the definition of T2DM “remission” in the study cohort. 
This was not significantly different from the 2.2% (1.34% - 3.54%) of the 2014 
Kaiser Permanente report on ≥ 65 year old population (20). It is significantly 
different from the Look AHEAD study which reported T2DM remission incidence 
of 11.5% (95% CI, 10.1%-12.8%) during the first year and 7.3% (95% CI, 6.2%-
8.4%) at 4 years in the intensive lifestyle intervention group. The percent 
“remission” in the present study did not differ from the 2.0% remission reported 
for the diabetes support and education control condition (DSE) group (P < 0.001) 
(19). The study presented here found that T2DM “remission” indeed occurs in 
Medicare patients 65 years and older who did not undergo bariatric surgery. 
These findings are consistent with previous findings and challenge the 
widespread notion that T2DM is irreversible in non-bariatric settings. 
Consistent with the 2014 Kaiser and the Look AHEAD studies, this study 
also found that the absence of hyperlipidemia was associated with T2DM 
“remission.” As suggested in previous findings, hyperlipidemia, obesity, and 
impaired glucose tolerance may have common biological pathway commonly 
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called metabolic syndrome. These findings provide additional evidence of the 
role of managing impaired lipid metabolism to slow or reverse T2DM progression. 
Further, this study evaluated multiple clinical conditions related to 
macrovascular and microvascular comorbidities that are typically associated with 
T2DM. After adjusting for covariates this study found a number of variables 
associated with T2DM “remission” that were not previously reported: no statin 
use; low diabetes complications severity index score; no hypertension; no 
neuropathy; no retinopathy; race (non-white and non-African American); 
presence of other chronic ischemic heart disease (IHD) and females (p<0.05). 
Gender: Globally, males are more likely to have T2DM than females (157, 158). 
This trend has changed over the last 50 years. Previously, females were more 
likely to have diagnosed T2DM, but in recent years, the increasing sedentary 
lifestyle of males is attributed to their increased prevalence of T2DM (159, 160). 
In line with these studies the current study found that females were more likely to 
have a T2DM “remission” compared to males.  
Race: Consistent with previous studies the current study found that Hispanics 
and other non-white race (excluding African American) were more like to have a 
T2DM ”remission” in the Medicare 65 years and older population (p<0.05) (161). 
This finding emphasizes the need for public health policies to develop culturally 
sensitive interventions to help ameliorate racial disparities of T2DM disease 
management especially in the elderly population. 
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Hypertension: Previous studies indicated that hypertension and T2DM generally 
occur together and share several common risk factors such as obesity, 
inflammation, and insulin resistance. Hypertension and T2DM also share 
common pathways such as those associated with sympathetic nervous system 
(SNS) and renin-angiotensin-aldosterone system (RAAS) (164). The present 
study found that even in Medicare patients 65 years and older population the 
absence of hypertension is associated with T2DM “remission” (p<0.05). 
Statins: This study evaluated the role of statins on T2DM “remission” and found 
that the absence of statin use is associated with T2DM “remission” (p<0.05). 
There is no previous literature on the role of statin in T2DM “remission.” 
However, its role on T2DM onset is well established. Statin therapy is associated 
with a 9% increased risk of T2DM (163). Prior investigation also established that 
the level of statin potency is associated with T2DM onset (182).  
DCSI score: The complications associated with T2DM usually develop 
simultaneously or consecutively rather than independently. A simple indicator for 
T2DM related complications may not have been a sufficient measure of T2DM 
disease progression. Therefore, in the present study, we used an indicator (or 
score), as previously described, to quantify the severity of diabetic complications 
(97, 98). This indicator is called the Diabetes Complications Severity Index 
(DCSI) and models the severity of diabetes complication at any given point of 
time in the patient’s life. Using the DCSI score, we further analyzed the 
association between severity of T2DM and T2DM “remission,” and found that 
lower DCSI scores (i.e., individuals who have less severe diabetes) are 
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associated with T2DM “remission.” This finding is important because DCSI can 
thus help in stratifying individuals with T2DM into groups based on score 
severity. This information can later be used for selecting individuals into disease 
management programs. 
Retinopathy: Retinopathy is one of the most common microvascular damage 
sites associated with T2DM. Diabetic retinopathy is a major public health 
problem, with approximately one third of T2DM patients developing some form of 
retinopathy (183). The healthy function of retina depends on availability of high 
amounts of oxygen, which in turn depends on intact blood-retinal barrier. The 
dysglycaemia associated with T2DM causes damage to this barrier by damaging 
both the inner retinal barrier and/or causing microvascular occlusions. The 
severity of such retinopathy might range from background retinopathy to 
complete blindness depending on the level of damage (184). Previous studies 
have recommended individuals with T2DM to control their blood sugar, blood 
pressure, and body fat to control the risk of development of advanced retinopathy 
(183). 
Evidence in the present study found that the absence of any T2DM 
retinopathy was associated with T2DM “remission (p<0.05). Taken in 
combination with previous recommendations, this study suggests that providers 
must educate T2DM about the possibility of “remission” by lifestyle modifications 
a self-incentive for enabling modified behavior, and that they still have a chance 
to reverse the progression of T2DM. 
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Neuropathy: Neuropathy and diabetes are generally associated together. More 
than 50% of T2DM individuals have neuropathy and more than 50% of 
individuals with neuropathy have T2DM (89). The study presented here found 
that the absence of neuropathy was associated with T2DM “remission” in 
Medicare patients 65 years and older.  
Neuropathy can be associated with several causes, including metabolic 
injury (hyperglycemia), compressive injury, ischemic injuries, inflammatory and/or 
immune response, and other comprehensive etiologies (185). This study did not 
evaluate the specific reason associated with neuropathy due to the lack of 
access to physician notes. In spite of this limitation, this finding provides valuable 
insight into designing public health interventions; for example, individuals with 
T2DM and without neuropathy may be educated about this finding to incentivize 
them to make behavior and lifestyle changes. 
Other Chronic IHD: IHD is the loss of elasticity and thickening of the coronary 
arteries, leading to progressive arterial insufficiency. Individuals with “other 
chronic IHD” were more likely to go into T2DM “remission.” This association is 
not completely understood. One explanation of this association is that there may 
be a small proportion of individuals in the study sample where the provider takes 
them off their diabetic medication due to a variety of reasons, such as, the 
caregiver is less aggressive in motivating patients to achieve lower HbA1c levels. 
Another explanation for this association is that individuals who have certain 
clinical conditions, such as those related to cardiovascular diseases, might be on 
constant alert to make healthier choices, especially due to the constant 
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reminders that they might be receiving from their provider, insurance agency. 
These factors, and others, may be the reason why these individuals have a 
different outcome compared to those without this clinical condition. 
There were several limitations to this study. First and most important, the 
study does not include clinical and laboratory findings such as physician notes 
and HbA1c lab results, which would have provided a more accurate measure of 
T2DM “remission.” Therefore, a small proportion of individuals could have been 
asked by their doctors to stop taking T2DM medication for a variety of unknown 
reasons as noted. The probability of this occurring in the data is very low 
because even in those cases the physician will probably capture the T2DM 
related diagnostic code on the medical claims. Also, as with other similar 
retrospective studies there is a potential for error in information coded in the 
administrative data. As in other retrospective studies it is not possible to establish 
causation with such an analytic approach. The level or potency of the T2DM 
medications including statins was not evaluated in this analysis. DCSI is an 
unweighted composite index, and does not independently test individual 
outcomes associated with each complication associated with T2DM. Metabolic 
syndrome is also excluded from the study due to lack of data such as BMI and 
physician notes. 
In conclusion, T2DM “remission” in Medicare patients 65 years and older 
is observed in a community setting in a small proportion of individuals who did 
not undergo bariatric surgery. In majority of the remaining patients T2DM may 
still remain a major burden and impact quality of life. This study helps establish 
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additional evidence to the role of lifestyle intervention in T2DM progression and 
provides some insights into the possibility of using behavior and lifestyle 
interventions as alternate pathways for diabetes treatment and management.  
Lifestyle interventions such as increased physical activity, low 
carbohydrate diet, cessation of tobacco smoking, and reducing alcohol intake are 
already recommended by providers to T2DM patients as a means to control 
glucose, blood pressure and cholesterol. These study results can further help 
providers discuss disease prognosis with their T2DM patients and in designing 
efficacious interventions to the right individuals at the right time. This will help 
design better T2DM management programs. For example, if a Medicare patient 
65 years and older individual is diagnosed with T2DM and has not yet developed 
any chronic comorbidities such as neuropathy or retinopathy, but has modifiable 
comorbidities such as hypertension and hyperlipidemia, then their provider can 
use the insights provided in this study to advise their patients about their 
possibility to control their T2DM progression by participating in lifestyle 
intervention programs. DCSI score can be used as an index to further tailor these 
management programs. 
These findings also have significant public health implications ranging 
from health policy, clinical guidance design, built environment and incentives to 
enable the success of these lifestyle intervention programs. Lastly, this study 
recommends further investigation into the lifestyle pathway for T2DM “remission” 
to improve our understanding of this beneficial alternative. Thus, it may be 
 
81 
 
possible to increase the percent of individuals who might benefit from T2DM 
“remission.” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: The tables and figures are placed at the end of the article as per the 
requirement of the journal. 
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Tables and Figure Legends 
 
Table 5.1: Baseline demographic and T2DM “remission” characteristics 
Characteristic  
No “Remission”* 
(n = 9,559) 
“Remission”† 
(n = 500) P value  
Age, mean (SD), years 72.6 (5.1) 73.7 (5.5) <.0001 
Female sex 57.2% 62.2% 0.0273 
Race/ethnicity     0.3542 
White 7,679 (80.4) 397 (79.6)   
Black 1,378 (14.4) 68 (13.6)   
Others 497 (5.2) 34 (6.8)   
 
Data are represented as n (%), unless otherwise mentioned 
*Missing data in no “remission” cohort: Race (n = 5)  
†Missing data in "remission" cohort: Race (n = 1) 
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 Table 5.2: Baseline comorbidities 
Characteristic  
No 
“Remission"* 
(n = 9,559) 
“Remission”† 
(n = 500) P value  
Hypertension 8,285 (86.7) 411 (82.2) 0.0040 
Hyperlipidemia 8,125 (85.0) 402 (80.4) 0.0050 
Retinopathy 1,187 (12.4) 32 (6.4) <0.0001 
Diabetic ophthalmologic disease 830 (8.7) 17 (3.4) <0.0001 
Background retinopathy 392 (4.1) <10 0.0010 
Other retinopathy 138 (1.4) <10 0.6550 
Retinal edema 67 (0.7) <10 0.0600 
Cystoid macular 
edema/degeneration 64 (0.7) <10 0.2010 
Other retinal disorders 40 (0.4) <10 0.9500 
Proliferative retinopathy 61 (0.6) <10 0.0730 
Retinal detachment 72 (0.8) <10 0.1550 
Blindness 55 (0.6) <10 0.0220 
Vitreous hemorrhage 21 (0.2) <10 0.4110 
Neuropathy 1,801 (18.8) 68 (13.6) 0.0030 
Diabetic neuropathy 1,395 (14.6) 46 (9.2) 0.0010 
Mononeuropathy 356 (3.7) 19 (3.8) 0.9310 
Charcot’s arthropathy <10 <10 0.1870 
Polyneuropathy 820 (8.6) 20 (4.0) <0.0001 
Neurogenic bladder 15 (0.2) <10 0.8140 
Autonomic neuropathy 78 (0.8) <10 0.3070 
Gastroparesis/diarrhea 44 (0.5) <10 0.3950 
Orthostatic hypotension 145 (1.5) 10 (2.0) 0.3930 
Cerebrovascular 841 (8.8) 42 (8.4) 0.7590 
Transient ischemic attack (TIA) 168 (1.8) 11 (2.2) 0.4660 
Stroke 759 (7.9) 38 (7.6) 0.7840 
Cardiovascular 2,925 (30.6) 174 (34.8) 0.0470 
Atherosclerosis 572 (6.0) 36 (7.2) 0.2660 
Other ischemic heart disease  112 (1.2) <10 0.3900 
Angina pectoris 309 (3.2) 16 (3.2) 0.9680 
Other chronic ischemic heart 
disease  1,846 (19.3) 94 (18.8) 0.7770 
Myocardial infarction 81 (0.8) 10 (2.0) 0.0080 
Ventricular fibrillation, arrest 732 (7.7) 43 (8.6) 0.4410 
Atrial fibrillation, arrest 11 (0.1) <10 0.5920 
Other atherosclerotic 
cardiovascular disease 138 (1.4) 10 (2.0) 0.3140 
Old myocardial infarction 462 (4.8) 25 (5.0) 0.8650 
Heart failure 503 (5.3) 34 (6.8) 0.1360 
Atherosclerosis, severe <10 <10 0.6090 
Aortic aneurysm/dissection 121 (1.3) 17 (3.4) <0.0001 
Peripheral vascular disease 1,074 (11.2) 60 (12.0) 0.5980 
 
84 
 
Characteristic  
No 
“Remission"* 
(n = 9,559) 
“Remission”† 
(n = 500) P value  
Diabetic PVD 524 (5.5) 16 (3.2) 0.0270 
Other aneurysm, lower extremity <10 <10 0.0090 
Peripheral vascular disease 807 (8.4) 51 (10.2) 0.1700 
Foot wound + complication <10 <10 0.7460 
Claudication, intermittent 623 (6.5) 46 (9.2) 0.0190 
Embolism/thrombosis (lower 
extremity) <10 <10 0.0440 
Gangrene <10 <10 0.6470 
Gas gangrene <10 <10 0.8190 
Ulcer of lower limbs 98 (1.0) <10 0.3530 
Metabolic 46 (0.5) <10 0.3230 
Ketoacidosis 16 (0.2) <10 0.8630 
Hyperosmolar 22 (0.2) <10 0.4480 
Other coma <10 <10 0.3960 
Data are expressed as n (%). Baseline year = 2011 
If the number of individuals in a cell were less than 10, the number is replaced 
with “< 10” 
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            Figure 5.1: Unadjusted Cox proportional hazard for T2DM “remission” 
 
ASCVD, atherosclerotic cardiovascular disease; DCSI, Diabetes 
complications severity index; IHD, ischemic heart disease. Race: other, 
non-white and non-African American; PVD, peripheral vascular disease. 
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        Figure 5.2: Adjusted Cox proportional hazard for T2DM “remission” 
 
DCSI: Diabetes complications severity index; IHD, ischemic heart disease; 
Race: other, non-white and non-African American.
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Appendix: Table 5.1: T2DM “remission” definitions 
 T2DM Diagnosis   
2008§ 2009 2010 2011 2012 2013 2014 2015 PATTERN§§ Description 
YES YES YES YES YES YES YES YES 11111111 No “Remission”  
( n = 9,559) 
YES YES YES YES YES YES YES NO 11111110  
“Remission” 
(n = 500) 
YES YES YES YES YES YES NO NO 11111100 
YES YES YES YES YES NO NO NO 11111000 
YES YES YES YES NO NO NO NO 11110000 
YES YES YES NO NO NO NO NO 11100000 “Remission”  
(Excluded) YES YES NO NO NO NO NO NO 11000000 
YES NO NO NO NO NO NO NO 10000000 
YES YES YES YES NO NO YES YES 11110011 “Remission” + 
Relapse 
(Excluded) 
YES YES YES YES NO YES NO YES 11110101 
§NO = no type 2 diabetes diagnosis, and YES = type 2 diabetes diagnosis 
§§0 = no T2DM and 1 = presence of T2DM
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Appendix: Table 5.2 - Unadjusted and adjusted Cox proportional hazard for “remission” 
  Any “Remission” (n = 500)   
  Hazard Ratio (95% CI)   
Characteristic n (%) Unadjusted P Value Fully adjusted P value 
Gender           
Males  189 (4.4) 1.0 (ref)   1.0 (ref) <0.0001  
Females  311 (5.3) 1.26 (1.12 - 1.42) <0.0001 1.33 (1.18 - 1.50)   
Race           
White 397 (4.92) 1.0 (ref)   1.0 (ref)   
Black 68 (4.7) 0.93 (0.78 - 1.10) 0.3936  1.01 (0.85 – 1.20  0.8849 
Other 34 (6.4) 1.51 (1.21 - 1.87) 0.0002 1.49 (1.21 - 1.86)  0.0002 
DCSI Score           
Zero 293 (7.7) 1.0 (ref) <0.0001  1.0 (ref)  <0.0001 
1-2 152 (3.7) 0.48 (0.42 - 0.55)   0.67 (0.57 - 0.79)   
3+ 55 (2.6) 0.36 (0.29 - 0.44)   0.69 (0.54 - 0.89)   
Statins           
No statins 145 (9.32) 1.0 (ref)   1.0 (ref)  <0.0001 
Statins 355 (4.17) 0.47 (0.42 - 0.53) <0.0001 0.61 (0.53 - 0.69)   
Clinical Conditions           
No hypertension 33 (13.92) 1.0 (ref)   1.0 (ref)  <0.0001 
Hypertension 467 (4.75) 0.36 (0.31 - 0.41) <0.0001 0.48 (0.42 - 0.55)   
No hyperlipidemia 25 (9.43) 1.0 (ref)   1.0 (ref) <0.0001  
Hyperlipidemia 475 (4.85) 0.38 (0.34 - 0.43) <0.0001 0.60 (0.52 - 0.69)   
Retinopathy           
No retinopathy 411 (6.39) 1.0 (ref) <0.0001  1.0 (ref) <0.0001  
Retinopathy 89 (2.45) 0.19 (0.13 - 0.27)  0.25 (0.17 - 0.36)   
Neuropathy           
No neuropathy 322 (6.85) 1.0 (ref) <0.0001  1.0 (ref) <0.0001  
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  Any “Remission” (n = 500)   
  Hazard Ratio (95% CI)   
Characteristic n (%) Unadjusted P Value Fully adjusted P value 
Neuropathy 178 (3.32) 0.33 (0.28 - 0.41)  0.45 (0.37 - 0.56)   
Cardiovascular           
No other ASCVD 476 (5.49) 1.0 (ref) 0.0202  1.0 (ref) 0.3796  
Other ASCVD 24 (1.74) 0.70 (0.52 - 0.95)  0.86 (0.62 - 1.19)  
No other chronic IHD 340 (5.45) 1.0 (ref) 0.0106  1.0 (ref) <0.0001  
Other Chronic IHD 160 (4.19) 0.83 (0.71 - 0.96)  1.57 (1.29 - 1.91)   
Peripheral vascular Disease            
No peripheral vascular disease 380 (5.65) 1.0 (ref) <0.0001  1.0 (ref)  0.1625 
Peripheral vascular disease 120 (3.6) 0.53 (0.43 - 0.66)   0.85 (0.67-1.07)  
 
Fully adjusted model includes all variables in this table 
*Missing data in No “remission” cohort: race (n = 5), in "remission" cohort: race (n = 1)  
If the number of Individuals in a cell was < 10, the number is replaced with “< 10” 
Data represented as n (%) for baseline year (2011)
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CONCLUSIONS 
Type 2 diabetes mellitus is a progressive chronic disease condition. If left 
unmanaged, the body’s ability to regulate blood sugar deteriorates gradually. The 
complications associated with dysglycemia can have deleterious effects on the 
quality of life of the patient. In order to develop effective intervention programs, it 
is first important to understand the prognosis of T2DM. In this regards, the study 
presented here investigated two key sub components of T2DM progression: a) 
onset of T2DM; b) “remission” of T2DM in a non-bariatric setting.   
Using two different study cohorts the study presented here identified key 
factors that are associated with T2DM onset and “remission” in Medicare patients 
65 years and older. The factors that were significantly associated with T2DM 
onset were: male gender; non-white ethnicity (African American, Hispanics); 
statin use; hypertension; hyperlipidemia; heart failure; ulcer of lower limbs; 
atherosclerosis; other retinopathy; angina pectoris; blindness and low vision; 
absence of other chronic ischemic heart disease (IHD) (p<0.05). The factors 
associated with T2DM “remission” were no statin use; low diabetes complications 
severity index score (DCSI); no hypertension; no hyperlipidemia; no neuropathy; 
no retinopathy (p<0.05). Race (Asian/Hispanic); other chronic ischemic heart 
disease (IHD); and female gender were significantly associated with T2DM 
“remission” (p<0.05). 
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The combined results of the onset and “remission” study suggests that 
hypertension, hyperlipidemia, statin use, gender, and race are some of the 
common factors associated with both T2DM onset and “remission.” Hypertension 
and hyperlipidemia are key components of metabolic syndrome. Statins are used 
for cardiovascular disease risk reduction in patients with metabolic syndrome 
(186). These findings suggest that further investigation in the role of metabolic 
syndrome in T2DM progression is warranted for future studies.  
This study also found that lower DCSI scores were associated with T2DM 
“remission.” This finding can help in stratifying individuals with T2DM into groups 
based on their diabetes severity. This information can thus be used for selecting 
individuals into disease management programs.  
The sociodemographic and clinical profile of Medicare patients 65 years 
and older with T2DM onset and T2DM “remission” could be used to: a) educate 
T2DM patients, providers, payors and other stakeholders; b) develop T2DM 
management programs; c) design public health policies. This will in turn help to 
improve quality of life and reduce T2DM disease burden.   
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Limitations  
There were several limitations to this study as described below. 
a) Lack of data: First and most important, the study does not include clinical and 
laboratory findings such as physician notes and HbA1c, which would have 
provided a more accurate measure of T2DM onset and T2DM remission. This is 
especially important in the “remission” cohort because there could be a small 
proportion of individuals who were asked by their doctors to stop taking T2DM 
medication in order to decrease the stress on the body, or the individual might 
have other reasons to stop taking medication, or get prescription samples for 
diabetes medication, or pay out of pocket for their T2DM medication. The 
probability of not identifying individual’s T2DM status due to these reasons would 
be low because even in the absence of pharmacy claims, an individual’s medical 
claims are often captured as diagnostic on the medical claims. 
Data such as nutrition, physical activity, BMI, original diagnosis date for 
T2DM are also not available. The study does not further split the study cohort 
based on pre-diabetes and/or undiagnosed individuals. 
Individuals with metabolic syndrome cannot be identified due to lack of 
data such as BMI and cholesterol data. 
b) Coding error: As with other similar retrospective studies there is a potential 
for error in the information coded on the administrative data. Even though the 
claims are audited on a regular basis there is a possibility of potential for error in 
the information coded on medical claims due to provider error, fraud etc. 
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c) Causation: As with similar studies, this type of analysis can only establish 
associations and is not intended to establish causation of T2DM onset or 
“remission”. 
d) Complexity: This study is a quasi-experiment (i.e., it’s not a true randomized 
study). The factors (covariates, confounding variables, etc.) will not be random 
and will not be able to completely eliminate bias or confounding. 
e) Dosage of T2DM drug and statin: The level or potency of the T2DM 
medications and statins was not evaluated in this analysis.  
f) DCSI score: is an unweighted composite index, and does not independently 
test individual outcomes associated with each complication associated with 
T2DM. 
g) Generalizability: The exclusions such as excluding disabled individuals, 
excluding individuals with ESRD, excluding individuals with chronic kidney 
function in the study cohort limits the generalizability of the study to the overall 
Medicare population. 
Strengths  
The medical and pharmacy data being studied here are part of a 
standardized data collection practice of the health insurance organization. The 
data is collected using a standardized process with standard protocols for 
extraction, transformation and loading (ETL). The data is audited by the 
organization for its business purposes and hence less prone to data integrity 
issues. 
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